Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views

Moon Jong Kim 1,†, Yuanjian Huang 1,†,* and Jae-Il Park 1,2,3,*

1 Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; mkim312@mdanderson.org (M.J.K.); yhuang14@mdanderson.org (Y.H.)
2 Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center and Health Science Center, Houston, TX 77030, USA
3 Program in Genetics and Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
* Correspondence: jaeil@mdanderson.org
† These authors contributed equally.

Received: 27 October 2020; Accepted: 1 December 2020; Published: 4 December 2020

Simple Summary: Therapeutic targeting of Wnt has long been suggested for gastrointestinal (GI) cancer treatment because deregulation of Wnt signaling is associated with GI cancers. However, therapeutic targeting of Wnt is still challenging because of the pleiotropic roles of Wnt signaling in the human body. Thus, targeting strategies of Wnt signaling are continuously evolving. The current flows of targeting Wnt signaling for cancer treatment are focused on increasing the specificity of drugs and combinatory treatment with other cancer drugs that minimize side effects and increase efficacy. Additionally, increased knowledge about the β-catenin paradox has expanded the cases that can be treated with Wnt targeting therapy, not strictly considering Wnt upstream and downstream mutations. Here, we discuss these evolving views of targeting Wnt signaling and describe examples of current clinical trials.

Abstract: Wnt signaling governs tissue development, homeostasis, and regeneration. However, aberrant activation of Wnt promotes tumorigenesis. Despite the ongoing efforts to manipulate Wnt signaling, therapeutic targeting of Wnt signaling remains challenging. In this review, we provide an overview of current clinical trials to target Wnt signaling, with a major focus on gastrointestinal cancers. In addition, we discuss the caveats and alternative strategies for therapeutically targeting Wnt signaling for cancer treatment.

Keywords: Wnt signaling; β-catenin; cancer; gastrointestinal cancers; therapeutic targeting of Wnt signaling; β-catenin paradox; molecular targeting

1. Introduction

Evolutionarily conserved Wnt signaling was initially identified in Drosophila (Wingless) and the mammalian system (Int-1) [1,2]. Wnt signaling has been extensively studied, revealing its pivotal roles in orchestrating embryonic development, tissue homeostasis, and regeneration [3–5]. Notably, the deregulation of Wnt signaling is associated with many human diseases, including cancers [6]. Therefore, the manipulation of Wnt signaling has gained attention as a means of disease treatment and prevention [7,8].

Although it has been confirmed in in vitro and in vivo cancer studies that targeting Wnt signaling has drastic tumor-suppressing effects, no targeted drugs have been successively advanced to clinical applications to date [7–9]. This is mainly because Wnt signaling plays essential roles in maintaining a
broad range of physiological events [3–5]. Therefore, blocking Wnt signaling has detrimental impacts on tissue homeostasis and regeneration. In this review, we discuss current views on therapeutically targeting Wnt signaling and describe related clinical trials in gastrointestinal (GI) cancer.

2. Wnt Signaling

Wnt signaling is an autocrine and paracrine signal-transducing module that is activated by lipid-modified WNT ligands and their receptors [10,11]. In humans, 19 WNT ligands and 18 receptors and coreceptors have been identified [10,12]. The Wnt ligand–receptor interaction activates a downstream cascade in a β-catenin-dependent or -independent manner [13] (Figure 1).

β-catenin is an Armadillo repeat protein that is mainly associated with E-cadherin at the inner plasma membrane. The β-catenin level is tightly regulated by the protein destruction complex, which is composed of the axis inhibitor (AXIN1), adenomatous polyposis coli (APC), casein kinase 1 (CK1), glycogen synthase kinase 3 (GSK3), and β-transducin repeat-containing protein (βTrCP) and induces β-catenin degradation through phosphorylation-mediated ubiquitination [11,14–17].
In β-catenin-dependent Wnt signaling (canonical Wnt signaling), the destruction complex is sequestered upon WNT ligand stimulation and disrupted by the formation of the WNT-receptor-disheveled (DVL) complex [18], resulting in the stabilization and nuclear translocation of β-catenin [19]. Next, nuclear β-catenin interacts with the TCF/LEF transcription factor family (TCF7, LEF1, TCF7L1, and TCF7L2), which recruits coactivators to transactivate downstream target genes [20–23]. β-catenin-independent Wnt signaling (also referred to as non-canonical Wnt signaling) activates downstream modules through the planar cell polarity (Wnt/PCP) pathway or Wnt/Ca\(^{2+}\) signaling pathway [10] (Figure 1).

In the Wnt/PCP pathway, the binding of WNT-FZDs triggers a cascade involving small GTPases RHOA (transforming protein RhoA) and RAC1 (Ras-related C3 botulinum toxin substrate 1), which in turn activates ROCKs (Rho-associated protein kinases) and JUN-N-terminal kinases, respectively [10,24,25]. It mainly regulates cell polarity, cell motility, and morphogenetic movements [10,24,25]. In the Wnt/Ca\(^{2+}\) signaling pathway, the binding of WNT-FZDs activates phospholipase C (PLC), which in turn triggers the release of Ca\(^{2+}\) from intracellular stores and the activation of effectors such as calcium- and calmodulin-dependent protein kinase II (CAMKII), protein kinase C (PKC), and calcineurin (CaN) [10,26]. CaN activates the nuclear factor of activated T cells, which regulates the transcription of the genes that control cell fate and cell migration [10,26]. Although both β-catenin-dependent and -independent Wnt signaling are involved in tumorigenesis, β-catenin-dependent Wnt signaling is relatively well defined in various cancer models. In line with this, current pharmacological trials targeting Wnt signaling have mainly focused on β-catenin-dependent Wnt signaling.

3. Wnt Signaling Alteration in GI Cancers

Hyperactivation of Wnt signaling is frequently observed in GI cancers, including colorectal cancer (CRC), hepatocellular carcinoma, gastric cancer, and pancreatic cancer. Approximately 90% of CRC demonstrates Wnt signaling-related gene alterations [27]. More than 70% of the genetic alterations in CRC are APC mutations [27,28]. Unlike CRC, APC mutations are rare in hepatocellular carcinoma. Hepatocellular carcinoma mainly displays CTNNB1 mutations (20–35%) [29], AXINI mutations (8–15%) [30], and Frizzled-7 (FZD7) overexpression (90%) [31]. In addition to mutations in the negative feedback regulator of the FZD receptor, the E3 ubiquitin-protein ligases ZNRF3 and RNF43 and their ligands, R-spondins (RSPOs), are frequently observed in pancreatic and gastric cancers [32,33].

4. Therapeutically Targeting Wnt Signaling in GI Cancer

Targeting Wnt signaling for cancer treatment normalizes the hyperactivated Wnt signaling that promotes cancer progression. For this purpose, many targeting strategies have been evaluated, including the inhibition of Wnt ligands and receptors or coreceptors, restoration of the destructive complex, and inhibition of β-catenin/β-catenin-dependent transcriptional machinery. Although these approaches have not been studied in phase III clinical trials or used clinically, dozens of Wnt-targeting agents are currently being evaluated in phase II clinical trials (Table 1). These important phase II clinical trials include LGK974, genistein, Foxy-5, DKN-01, niclosamide, PRI-724, and chloroquine/hydroxychloroquine.

In the next section, we provide an overview of the known and potential agents that target Wnt signaling, especially for GI cancers; we also describe their mechanisms of action and related clinical trials (Table 2). All potential agents that inhibit Wnt signaling are listed in Table 3. In addition, the molecular targets of representative Wnt inhibitors on WNT signaling are illustrated in Figure 2.

| Table 1. Agents inhibiting Wnt signaling for GI cancers in phase II clinical trials. |
|---|---|---|---|
| Agent | Mechanism | Trial | Cancer |
| LGK974 | PORCN inhibitor | NCT02278133 | BRAF V600-mutated metastatic colorectal cancer |
| Genistein | SFRP2 silencer inhibitor | NCT01985763 | Metastatic colorectal cancer |
| Foxy-5 | WNT5A mimic | Vermorken 2019 | WNT5A-negative colon cancer |
Table 1. Cont.

| Agent          | Mechanism                               | Trial                     | Cancer                                                                 |
|----------------|-----------------------------------------|---------------------------|------------------------------------------------------------------------|
| DKN-01         | Monoclonal antibody against DKK1        | NCT03645980; NCT04166721 | Advanced hepatocellular carcinoma; Advanced gastroesophageal adenocarcinoma |
| Niclosamide    | FZD1 inhibitor, LRP6 inhibitor          | NCT02519582               | Progressed colorectal cancer                                           |
| PRI-724        | β-catenin/CREBBP inhibitor              | NCT02413853               | Metastatic colorectal adenocarcinoma                                   |
| Chloroquine    | v-ATPase inhibitor                      | NCT02496741               | Advanced colorectal cancer, including intrahepatic cholangiocarcinoma  |
| Hydroxychloroquine | v-ATPase inhibitor (total 13 trials)    | NCT01006369, etc.        | Advanced colorectal carcinoma; Advanced hepatocellular carcinoma; Advanced cholangiocarcinoma; Pancreatic adenocarcinoma |

Figure 2. Wnt targeting agents for the Wnt/β-catenin signaling pathway. Wnt targeting agents for GI cancers mainly focus on the inhibition of the key molecules in Wnt/β-catenin signaling, such as inhibiting WNT ligands (ipafrect, LGK794), inhibiting Wnt receptors/coreceptors (vantictumab, rosmantuzumab), stabilizing the destruction complex (AZ1366, hydroxychloroquine), and inhibiting β-catenin-dependent transcriptional machinery (MSAB, PRI-724).
| Trial                    | Agent       | Mechanism               | Design                  | Cancer                                                                 | Interventions                                                                 | Status          |
|-------------------------|-------------|-------------------------|-------------------------|------------------------------------------------------------------------|-------------------------------------------------------------------------------|-----------------|
| NCT02675946             | CGX1321     | Porcupine inhibitor     | Phase I; Single group   | Advanced GI cancers                                                   | CGX1321; CGX1321 + pembrolizumab                                           | Recruiting      |
| NCT03507998             | CGX1321     | Porcupine inhibitor     | Phase I; Single group   | Advanced GI cancers                                                   | CGX1321                                                       | Recruiting      |
| Ng 2017 (NCT02521844)   | ETC-159     | Porcupine inhibitor     | Phase I; Single group   | Advanced solid malignancies, including colorectal cancer, etc.         | ETC-159; ETC-159 + pembrolizumab                                          | Ongoing         |
| NCT01351103             | LGK974      | Porcupine inhibitor     | Phase I; Single group   | Solid malignancies, including esophageal squamous-cell carcinoma, pancreatic adenocarcinoma, BRAF-mutated colorectal cancer, etc. | LGK974; LGK974 + spartalizumab                                               | Recruiting      |
| NCT02278133             | LGK974      | Porcupine inhibitor     | Phase II; Single group  | BRAF V600-mutated metastatic colorectal cancer with RNF43 mutations and/or R-spondin fusions | LGK974 + LGX818 + cetuximab                                                 | Completed       |
| Pintova 2019 (NCT01985763) | Genistein | SFRP2 silencer inhibitor | Phase II; Single group  | Metastatic colorectal cancer                                           | Genistein + FOLFOX; Genistein + FOLFOX + bevacizumab                           | Completed       |
| Jimeno 2017 (NCT01608867) | Ipafricept (OMP-54F28) | WNT decoy receptor      | Phase I; Single group   | Solid malignancies, including pancreatic cancer, colorectal cancer, etc. | Ipafricept                                                                      | Completed       |
| Dotan 2019 (NCT02050178) | Ipafricept (OMP-54F28) | WNT decoy receptor      | Phase I; Single group   | Metastatic pancreatic ductal adenocarcinoma                           | Ipafricept + nab-paclitaxel + gemcitabine                                    | Completed       |
| NCT02069145             | Ipafricept (OMP-54F28) | WNT decoy receptor      | Phase I; Single group   | Advanced hepatocellular carcinoma                                     | Ipafricept + sorafenib                                                       | Completed       |
| NCT02020291             | Foxy-5      | WNT5A mimic             | Phase I; Single group   | Metastatic breast, colon, prostate cancer                              | Foxy-5                                                                               | Completed       |
| NCT02659552             | Foxy-5      | WNT5A mimic             | Phase I; Single group   | Metastatic breast, colon, prostate cancer                              | Foxy-5                                                                               | Completed       |
| Trial                  | Agent              | Mechanism               | Design                          | Cancer                                    | Interventions                                      | Status              |
|-----------------------|--------------------|-------------------------|---------------------------------|-------------------------------------------|---------------------------------------------------|---------------------|
| Vermorken 2019 [38]   | Foxy-5             | WNT5A mimic             | Phase II; Randomized; Parallel   | WNT5A-negative colon cancer               | Foxy-5 vs placebo                                   | Recruiting          |
| Davis 2019 (NCT02005315) [39] | Vantictumab (OMP-18R5) | Monoclonal antibody against FZDs | Phase I; Single group           | Metastatic pancreatic ductal adenocarcinoma | Vantictumab + nab-paclitaxel + gemcitabine         | Terminated          |
| Ryan 2016 (NCT02013154) [40] | DKN-01             | Monoclonal antibody against DKK1 | Phase I; Non-randomized; Parallel | Recurrent or metastatic esophageal cancer, gastro-esophageal junction cancer | DKN-01; DKN-01 vs paclitaxel; DKN-01 vs pembrolizumab | Ongoing             |
| Eads 2016 (NCT02375880) [41] | DKN-01             | Monoclonal antibody against DKK1 | Phase I; Single group           | Advanced cholangiocarcinoma               | DKN-01 + gemcitabine + cisplatin                   | Ongoing             |
| NCT03645980           | DKN-01             | Monoclonal antibody against DKK1 | Phase II; Non-randomized; Sequential | Advanced hepatocellular carcinoma         | DKN-01 vs sequential DKN-01 + sorafenib            | Recruiting          |
| NCT04166721           | DKN-01             | Monoclonal antibody against DKK1 | Phase II; Single group           | Advanced gastroesophageal adenocarcinoma  | DKN-01 + atezolizumab                               | Recruiting          |
| Bendell 2016 (NCT02482441) [42] | Rosmantuzumab (OMP-131R10) | Monoclonal antibody against RSPO3 | Phase I; Single group           | Advanced solid malignancies, including metastatic colorectal cancer, etc. | OMP-131R10                                         | Completed           |
| NIKOLO trial (NCT02519882) [43] | Niclosamide       | FZD1 inhibitor, LRP6 inhibitor | Phase II; Single group           | Progressed colorectal cancer              | Niclosamide                                        | Recruiting          |
| NCT02687009           | Niclosamide       | FZD1 inhibitor, LRP6 inhibitor | Phase I; Single group           | Colorectal adenocarcinoma                 | Niclosamide                                        | Terminated          |
| NCT02726334           | BNC101            | Monoclonal antibody against LGR5 | Phase I; Single group           | Metastatic colorectal cancer              | BNC101; BNC101 + FOLFIrI                            | Terminated          |
| NCT01777477           | Chloroquine       | v-ATPase inhibitor      | Phase I; Single group           | Advanced pancreatic adenocarcinoma       | Chloroquine + gemcitabine                          | Completed           |
| Molenaar 2017 (NCT02496741) [44] | Chloroquine       | v-ATPase inhibitor      | Phase II; Single group           | Advanced solid malignancies, including intrahepatic cholangiocarcinoma | Chloroquine + metformin                            | Completed           |
| Trial                  | Agent             | Mechanism                 | Design                        | Cancer                                           | Interventions                                                                 | Status      |
|-----------------------|-------------------|---------------------------|-------------------------------|------------------------------------------------|--------------------------------------------------------------------------------|-------------|
| NCT01006369           | Hydroxy-chloroquine | v-ATPase inhibitor        | Phase II; Non-randomized; Parallel | Metastatic colorectal carcinoma | Hydroxychloroquine + FOLFOX6 vs Hydroxychloroquine + XELOX + bevacizumab       | Completed   |
| Mahalingam 2014       | Hydroxy-chloroquine | v-ATPase inhibitor        | Phase I; Single group         | Advanced solid malignancies, including colorectal cancer, etc. | Hydroxychloroquine + vorinostat                                                | Completed   |
| Boone 2015 (NCT01128296) | Hydroxy-chloroquine | v-ATPase inhibitor        | Phase II; Single group        | Unresectable pancreatic ductal adenocarcinoma | Hydroxychloroquine + gemcitabine                                                | Completed   |
| Loaiza-Bonilla 2015   | Hydroxy-chloroquine | v-ATPase inhibitor        | Phase II; Single group        | Advanced colorectal adenocarcinoma               | Hydroxychloroquine + FOLFOX + bevacizumab                                       | Completed   |
| Wolpin 2014 (NCT01273805) | Hydroxy-chloroquine | v-ATPase inhibitor        | Phase I; Single group         | Metastatic pancreatic cancer                    | Hydroxychloroquine                                                              | Completed   |
| Hong 2017 (NCT01494155) | Hydroxy-chloroquine | v-ATPase inhibitor        | Phase II; Single group        | Early pancreatic ductal carcinoma               | Short course radiation therapy preoperatively. Hydroxychloroquine + capcitabine postoperatively | Ongoing     |
| Karasic 2019 (NCT01506973) | Hydroxy-chloroquine | v-ATPase inhibitor        | Phase II; Randomized; Parallel | Advanced pancreatic adenocarcinoma               | Hydroxychloroquine + nab-paclitacel + gemcitabine vs nab-paclitacel + gemcitabine | Ongoing     |
| NCT01978184           | Hydroxy-chloroquine | v-ATPase inhibitor        | Phase II; Randomized; Parallel | Resectable pancreatic adenocarcinoma            | Hydroxychloroquine + nab-paclitacel + gemcitabine vs nab-paclitacel + gemcitabine | Completed   |
| NCT02013778           | Hydroxy-chloroquine | v-ATPase inhibitor        | Phase II; Single group        | Unresectable hepatocellular carcinoma           | Hydroxychloroquine + transarterial chemoembolization                            | Terminated  |
| Trial                      | Agent              | Mechanism                  | Design                   | Cancer                                      | Interventions                                                              | Status      |
|---------------------------|--------------------|----------------------------|--------------------------|---------------------------------------------|---------------------------------------------------------------------------|-------------|
| Arora 2019 (NCT02316340) [51] | Hydroxy-chloroquine | v-ATPase inhibitor          | Phase II; Randomized; Crossover | Metastatic colorectal cancer                | Hydroxychloroquine + vorinostat vs regorafenib                            | Completed   |
| NCT03037437               | Hydroxy-chloroquine | v-ATPase inhibitor          | Phase II; Non-randomized; Parallel | Advanced hepatocellular cancer              | Hydroxychloroquine + sorafenib vs sorafenib                              | Ongoing     |
| NCT03215264               | Hydroxy-chloroquine | v-ATPase inhibitor          | Phase II; Single group    | Metastatic colorectal cancer                | Hydroxychloroquine + entinostat + regorafenib                            | Suspended   |
| NCT03344172               | Hydroxy-chloroquine | v-ATPase inhibitor          | Phase II; Randomized; Parallel | Resectable pancreatic adenocarcinoma       | Hydroxychloroquine + gemcitabine + nab-paclitaxel + avelumab vs hydroxychloroquine + gemcitabine + nab-paclitaxel | Suspended   |
| NCT03377179               | Hydroxy-chloroquine | v-ATPase inhibitor          | Phase II; Single group    | Advanced cholangiocarcinoma                | ABC294640; Hydroxychloroquine + ABC294640                                 | Ongoing     |
| NCT03825289               | Hydroxy-chloroquine | v-ATPase inhibitor          | Phase I; Single group     | Advanced pancreatic cancer                 | Hydroxychloroquine + trametinib                                         | Ongoing     |
| NCT04132505               | Hydroxy-chloroquine | v-ATPase inhibitor          | Phase I; Single group     | KRAS-mutated metastatic pancreatic adenocarcinoma | Hydroxychloroquine + binimetinib                                           | Ongoing     |
| NCT04145297               | Hydroxy-chloroquine | v-ATPase inhibitor          | Phase I; Single group     | MAPK-mutated GI cancers                    | Hydroxychloroquine + ulixertinib                                          | Ongoing     |
| NCT04214418               | Hydroxy-chloroquine | v-ATPase inhibitor          | Phase II; Non-randomized; Sequential | KRAS-mutated advanced solid malignancies, including pancreatic adenocarcinoma, colorectal adenocarcinoma, etc. | Hydroxychloroquine + atezolizumab + cobimetinib                          | Ongoing     |
| El-Khoueiry 2013          | PRI-724            | β-catenin/CREBBP inhibitor  | Phase I; Single group     | Advanced solid malignancies, including colorectal cancer, etc. | PRI-724                                                                  | Terminated  |
Table 2. Cont.

| Trial          | Agent | Mechanism                      | Design                  | Cancer                                      | Interventions                                      | Status       |
|----------------|-------|--------------------------------|-------------------------|---------------------------------------------|---------------------------------------------------|--------------|
| Ko 2016 (NCT01764477) [53] | PRI-724 | β-catenin/CREBBP inhibitor      | Phase I; Single group   | Recurrent or advanced pancreatic adenocarcinoma | PRI-724 + gemcitabine                             | Completed    |
| NCT02413853    | PRI-724 | β-catenin/CREBBP inhibitor      | Phase II; Randomized; Parallel | Metastatic colorectal adenocarcinoma         | mFOLFOX6/Bevacizumab + PRI-724 vs mFOLFOX6/Bevacizumab | Withdrawn    |
| NCT03355066    | SM08502 | CLK inhibitor                   | Phase I; Single group   | Advanced solid malignancies, including pancreatic cancer, colorectal cancer, etc. | SM08502                                             | Recruiting   |

Table 3. All potential agents inhibiting Wnt signaling.

| Mechanism                  | Agents                                                                 |
|----------------------------|------------------------------------------------------------------------|
| PORCN inhibitor            | CGX1321, ETC-159, LGK974, GNF-6231, IWP-2, IWP-3, IWP-4, IWP-12, IWP-L6, IWP-O1, RXC004, WNT-C59 |
| SFRP1 inhibitor            | WAY-316606                                                              |
| SFRP2 silencer inhibitor   | Genistein                                                               |
| WNT5A mimic                | Foxy-5                                                                 |
| WNT inhibitor              | Ant1.4Br/Ant1.4Cl, wogonin                                             |
| WNT decoy receptor         | Ipafricept                                                             |
| WNT3A-LRP5 complex inhibitor | APCDD1                                                                |
| FZD inhibitor              | Vantictumab                                                            |
| FZD1&LRP6 inhibitor        | Niclosamide                                                             |
| FZD4 inhibitor             | FzM1                                                                   |
| FZD7 inhibitor             | Fz7-21                                                                  |
| FZD10 inhibitor            | OTSA101, OTSA101-DTPA-90Y                                               |
| LGR5 inhibitor             | BNC101                                                                 |
| LRP6 inhibitor             | Gigantol, salinomycin                                                  |
| FZD8-LRP6 heterodimer inhibitor | IGFBP-4                                                               |
Table 3. Cont.

| Mechanism                                | Agents                                                                 |
|------------------------------------------|------------------------------------------------------------------------|
| DKK1 inhibitor                           | DKN-01                                                                 |
| DVL-PDZ domain inhibitor                 | Compound 3289-8625, FJ9, NSC668036, peptide Pen-N3                    |
| RSPO3 inhibitor                          | Rosmuzutumab                                                            |
| TNKS inhibitor                           | 2X-121, AZ1366, AZ-6102, G007-LK, G244-LM, IWR-1, JW55, JW67, JW74, K-756, MN-64, MSC2504877, NVP-TNKS656, RK-287107, TC-E5001, WIK4, XAV939 |
| v-ATPase inhibitor                       | Apicularen, archazolid, bafilomycin, chloroquine, chondropsine, concanamycin, cruentaren, disulfiramthe, FR167356, FR177995, FR202126, hydroxychloroquine, indolyl, KM91104, lobatamide, NiK12192, oximide, salicylihamide, SB 242784, tributyltin chloride |
| CK1 activator                            | Pyrvinium                                                               |
| GSK3β fragment mimic                     | TCS 183                                                                |
| β-catenin inhibitor                      | 21H7, isoquercitrin, KY1220, KYA1797K, triptonide (NSC 165677, PG 492) |
| β-catenin degrader                       | MSAB, NRX-252114                                                        |
| β-catenin/TCF inhibitor                  | BC21, BC2059, CCT031374, CCT036477, CGP049090, CWP32228, ethacrynic acid, FH535, iCRT3, iCRT5, iCRT14, LF3, NLS-StAx-h, PKF115-584, PKF118-310, PKF118-744, PNU-74654, quercetin, ZTM000990 |
| TNIK inhibitor                           | KY-05009, NCB-0846                                                     |
| β-catenin/EP300 inhibitor                | IQ-1, windorphen, YH249/250                                              |
| β-catenin/CREBBP&EP300 inhibitor         | C-82, ICG-001, PRI-724, retinoids, vitamin D3                          |
| β-catenin/PYGO inhibitor                 | Pyrvinium                                                               |
| β-catenin/BCL9 inhibitor                 | Compound 22, carnosic acid, SAH-BCL9                                   |
| CLK inhibitor                            | SM08502                                                                |
| Wnt/β-catenin signaling inhibitor        | Adavivint (SM04690, lorecivivint), artesunate, cardamonin, cardionogen, CCT031374, diethyl benzylphosphonate, echinacoside, KY021111, pamidronic acid, specnuezhenide |
5. Targeting WNT Ligands

5.1. Inhibiting WNT Ligands

Ipafricept (OMP-54F28) is a recombinant receptor that is comprised of the cysteine-rich domain of FZD8 fused to the human IgG1 Fc domain; it inhibits Wnt signaling by neutralizing WNT ligands [54]. Three trials evaluated ipafricept and its combination therapies (Table 2). A phase I trial evaluated the best dosage of ipafricept and revealed grade 1–2 adverse events (AEs), including dysgeusia, decreased appetite, fatigue, and muscle spasms [36]. Another phase I trial evaluated ipafricept combined with nab-paclitaxel and gemcitabine in metastatic pancreatic cancer and revealed grade ≥ 3 AEs, including increased aspartate aminotransferase, nausea, maculopapular rash, vomiting, and decreased white blood cells [37].

Secreted frizzled-related proteins (SFRPs) bound directly to WNTs via the cysteine-rich domain, preventing the WNT–FZD interaction [55–57]. SFRPs also form dimers with FZDs via the respective cysteine-rich domain to activate or inhibit WNT3A/β-catenin signaling, depending on their concentration [58]. In the nucleus, SFRPs act as biphasic modulators of β-catenin-mediated transcription, which promotes TCF7L2 recruitment and transactivation of cancer stem cell-related genes by binding to the β-catenin’s C-terminus; however, they suppress transcriptional activities by binding to the N-terminus [59]. The phase II trial evaluated genistein, an SFRP2 silencer inhibitor, in combination with FOLFOX and bevacizumab in metastatic CRC; the study revealed mild AEs, including headaches, nausea, and hot flashes (Table 2) [35]. In addition, Wnt inhibitory factor 1 directly binds to WNTs through the Wnt inhibitory factor domain and prevents WNTs from transducing Wnt signaling [60]. Cerberus also binds to and inhibits WNTs, inhibiting Wnt signaling [61]. However, no agents mimicking Wnt inhibitory factor 1 and Cerberus have been identified.

5.2. Targeting Lipid Modification of WNT Ligands

The palmitoylation of WNT ligands by the protein-serine O-palmitoleoyltransferase porcupine in the endoplasmic reticulum [62] is essential for the maturation and extracellular secretion of WNT ligands. The palmitoylated WNT ligands bind to Wntless homolog in the Golgi and are ferried to the plasma membrane via secretory exosomes [63]. Porcupine inhibitors (CGX1321, ETC-159, and LGK974 [WNT794]), which suppress Wnt signaling by blocking the secretion of WNT ligands, are currently being evaluated in clinical trials (Table 2). A phase I trial evaluated the best dosage of ETC-159 and revealed well-tolerated AEs, including vomiting, anorexia, and fatigue, dysgeusia, and constipation [34]. The lipid modification of WNTs can be enzymatically removed by the palmitoleoyl-protein carboxylesterase NOTUM, thereby inhibiting Wnt signaling [64]. The NOTUM inhibitor, ABC99, is effective in the treatment of benefiting osteopenia and osteoporosis by enhancing Wnt signaling (Table 3) [64,65]. However, no agents have been identified that mimic NOTUM to inhibit GI cancers. Alternatively, metalloprotease TIKI1 (Trabd2a) acts as a protease to cleave eight amino acid residues of WNTs, resulting in oxidized WNT oligomers with minimized receptor binding capability in frogs [66,67]. However, no agents have been identified that mimic the impact of TRABD on Wnt signaling in humans.

6. Targeting Wnt Receptors and Co-Receptors

6.1. Antibodies against FZDs

Vantictumab (OMP-18R5) is a monoclonal antibody that binds to FZD 1, 2, 5, 7, and 8 and inhibits Wnt signal transduction [54]. A phase I trial evaluating the best dosage of vantictumab combined with nab-paclitaxel and gemcitabine in metastatic pancreatic cancer was terminated because of the increased risk of bone fracture [39]. Moreover, FZD5 has been identified as a dominant FZD receptor in RNF43-mutant pancreatic cancer cells and may be a therapeutic index [68]. However, no agents targeting FZD5 have been introduced.
6.2. Mimetic Agents Binding to FZDs

Initially, WNT5A was classified as a non-canonical Wnt family member. It activates Wnt/Ca\(^{2+}\) signaling by stimulating intracellular Ca\(^{2+}\) flux in zebrafish and frogs \cite{69–72}. In 2006, Mikels et al. found that WNT5A also activates canonical Wnt signaling via FZD4 and LRP5 \cite{73}. Intriguingly, WNT5A additionally inhibits WNT3A-induced canonical Wnt signaling via FZD2 and tyrosine-protein kinase transmembrane receptor ROR2 \cite{73,74}. Therefore, the function of WNT5A is considered not limited to the field of Wnt signaling and is more dependent on the context of receptors. Foxy-5, a WNT5A peptide mimic, reduces the metastatic capacity of invasive breast cancer via epithelial discoid domain-containing receptor 1 (DDR1), which decreases the motility and the invasive potential of breast epithelial cells \cite{75–77}. However, whether these mechanisms are also true in GI cancers remains unknown. Foxy-5 is being evaluated in phase I-II clinical trials of metastatic CRC, but no results have been published \cite{38} (Table 2).

6.3. Inhibiting LRP5/6

Given that dickkopf-related protein 1 (DKK1) inhibits Wnt signaling through its direct binding to LRP5/6 \cite{78,79}, DKK1 was initially considered a tumor suppressor in the β-catenin-dependent context. Conversely, several studies have shown that DKK1 promotes tumor cell proliferation, metastasis, and angiogenesis, which might be mediated by β-catenin-independent signaling \cite{80–86}. One available explanation is that DKK1 interacts with both glypican4 (GPC4) and the LRP/KREMEN complex to induce the endocytosis of LRP5/6, transforming the biochemical properties of FZDs and their cytoplasmic components from the Wnt/β-catenin pathway to the Wnt/PCP signaling axis \cite{87,88}. This mechanism activating β-catenin-independent signaling and inhibiting β-catenin-dependent signaling was validated in zebrafish and frogs \cite{87,88}.

On the basis of the tumorigenic role of DKK1, DKN-01, a DKK1 monoclonal antibody, was developed for cancer therapy. Four trials evaluating DKN-01 and its combination therapies are ongoing (Table 2). A phase I trial assessing DKN-01 combined with paclitaxel in advanced esophageal and gastroesophageal junction cancer revealed that 35% of patients experienced a partial response \cite{40,89}. Another phase I trial of the best dosage of DKN-01 combined with gemcitabine and cisplatin in advanced biliary cancer revealed that 33.3% of patients experienced a partial response \cite{41}. Sclerostin domain-containing protein 1 can activate or inhibit Wnt signaling by mimicking WNT ligands or by competing with WNT8 for binding to LRP6, respectively \cite{90,91}. However, no agents simulating sclerostin domain-containing protein 1 have been identified.

6.4. Accelerating the Degradation of FZD/LRP Receptors

Secreted RSPOs (RSPO1-3) and their receptors, RNF43/ZNRF3, are required to potentiate Wnt signaling in various development and tissue homeostasis contexts \cite{92–94}. In addition, leucine-rich repeat-containing G-protein-coupled receptors (LGRs, LGR4-6) are required for the interaction between RSPOs and their receptors \cite{92}. Without RSPOs and LGRs, RNF43/ZNRF3 induces the internalization and degradation of FZD receptors and negatively regulates Wnt signaling \cite{92,95,96}.

A phase I trial evaluated the best dosage of rosmantuzumab (OMP-131R10), a monoclonal antibody against RSPO3, for metastatic CRC; no results have been published (Table 2). BNC101, a monoclonal antibody against LGR5, demonstrated antitumor activity in multiple CRC patient-derived xenografts, but the clinical trial was terminated (Table 2) \cite{97}. Niclosamide, a teniacide in the anthelmintic family, promotes FZD1 endocytosis, inhibiting WNT3A/β-catenin signaling in CRC and osteosarcoma and inducing LRP6 degradation in prostate and breast cancer \cite{98–100}. The NIKOLO trial and NCT02687009 have been evaluating niclosamide in CRC (Table 2). The NIKOLO trial has revealed no drug-related AEs \cite{43}. 
7. Targeting the Destruction Complex

7.1. Inhibiting the DVL–FZD Interaction

In the presence of WNT ligands, DVLs bind to the cytoplasmic domain of FZDs via the PDZ (PSD95, DLG1, and ZO1) domain, which provides a platform for the interaction between the LRP’s tail and AXIN to recruit the destruction complex onto the cytoplasmic membrane [101,102]. This process inhibits destruction complex-mediated \(\beta\)-catenin protein degradation [93]. Several inhibitors (compound 3289-8625, FJ9, NSC668036, and peptide Pen-N3) that directly inhibit DVL binding with FZDs are currently being evaluated in preclinical studies (Table 3) [103–106].

7.2. Stabilizing AXIN

Tankyrase is a member of the poly ADP-ribose polymerase superfamily of proteins which mediates the PARsylation and proteasomal degradation of AXIN [107,108]. Tankyrase inhibitors (AZ1366, G007-LK, G244-LM, IWR-1, JW55, and XAV939) that stabilize AXIN and activate the destruction complex are being evaluated in preclinical studies (Table 3) [109–113]. The E3 ubiquitin–protein ligase SIAH, a potent activator of Wnt signaling, promotes the ubiquitination and proteasomal degradation of AXIN by interacting with a VxP motif in the GSK3-binding domain of AXIN [114]. Ubiquitin carboxyl-terminal hydrolase 7 (USP7), a potent negative regulator of Wnt/\(\beta\)-catenin signaling, promotes the deubiquitination and stabilization of AXIN by interacting with AXIN through its TRAF domain [115]. However, no agents that inhibit SIAH or mimic USP7 have been identified.

7.3. Stabilizing APC

Transmembrane protein 9 (TMEM9) binds to and facilitates the assembly of vacuolar-type H\(^+\)-ATPase (v-ATPase), resulting in enhanced vesicular acidification and trafficking for subsequent lysosomal degradation of APC and hyperactivation of Wnt/\(\beta\)-catenin signaling [116]. Conversely, pharmacological targeting of v-ATPase using bafilomycin, concanamycin, hydroxychloroquine, or KM91104 inhibits Wnt/\(\beta\)-catenin signaling and suppresses intestinal tumorigenesis (Table 3) [116]. Twenty trials are currently evaluating v-ATPase inhibitors (Table 2). A phase II trial assessing hydroxychloroquine combined with gemcitabine in unresectable pancreatic cancer revealed no dose-limiting AEs [46]. Another phase II trial revealed an increased overall response rate (38.2 vs. 21.1%; \(P = 0.047\)) but no survival benefits (hazard ratio, 1.14; 95% CI, 0.76–1.69; \(P = 0.53\)) when adding hydroxychloroquine to combination therapy with nab-paclitaxel and gemcitabine for advanced pancreatic cancer [50].

7.4. Activating CK1 and GSK3

CK1 and GSK3 sequentially phosphorylate \(\beta\)-catenin to induce the ubiquitination and proteasomal degradation of \(\beta\)-catenin [16]. Therefore, CK1 and GSK3 activators likely reduce the level of \(\beta\)-catenin that translocates into the nucleus, consequently inactivating Wnt signaling. pyrvinium, a CK1 activator that binds to the C-terminal regulatory domain of its isoform CK1A1, has been introduced, but it has not been evaluated in clinical trials (Table 3) [117]. In addition, no GSK3 activators have been introduced.

8. Targeting \(\beta\)-Catenin and \(\beta\)-Catenin-Dependent Transcriptional Machinery

8.1. Promoting \(\beta\)-Catenin Degradation

Methyl 3-[[4-methylphenyl)sulfonyl]amino] benzoate (MSAB) [12] binds to the Armadillo repeat domain of \(\beta\)-catenin and promotes its degradation [118]. NRX-252114, a protein–protein interaction enhancer, enhances the interaction between \(\beta\)-catenin and its cognate E3 ligase, potentiating the ubiquitination-mediated degradation of \(\beta\)-catenin [119]. No clinical trials have evaluated MSAB and NRX-252114.
8.2. Inhibiting the β-Catenin–TCF/LEF Complex

With its increased fold change, nuclear β-catenin replaces the transducin-like enhancer protein corepressor with coactivators by forming the β-catenin–TCF/LEF complex [93,120]. This complex transactivates Wnt target genes through its sequence-specific DNA binding and context-dependent interaction [121]. β-catenin-TCF/LEF complex inhibitors (BC21, iCRT3, and PKF115-584) were introduced in preclinical studies (Table 3) [122–124].

8.3. Manipulating TCF/LEF Phosphatases

TRAF2 and NCK-interacting protein kinase (TNIK) phosphorylates the serine 169 residue of TCF7L1 and the serine 154 residue of TCF7L2, acting as an activating kinase of the β-catenin-TCF/LEF transcriptional complex [125–127]. TNIK inhibitors (KY-05009 and NCB-0846) are being evaluated in preclinical studies [126,128] (Table 3). Serine/threonine-protein kinase NLK phosphorylates the threonine 155 and serine 166 residues of LEF1 and the threonine 178, 189 residues of TCF7L2, triggering their dissociation from DNA and inhibiting Wnt target gene transactivation [129,130]. Homeodomain-interacting protein kinase 2 (HIPK2) phosphorylates LEF1, TCF7L1, and TCF7L2 to dissociate them from DNA, which positively or negatively modulates Wnt/β-catenin signaling [131,132]. However, no agents targeting NLK and HIPK2 have been identified.

8.4. Inhibiting Coactivators

CREB-binding protein (CREBBP), histone acetyltransferase EP300, pygopus homolog (PYGO), and B-cell CLL/lymphoma 9 protein (BCL9) are coactivators that interact with the β-catenin–TCF/LEF complex [10]. PRI-724 competes with β-catenin to bind with CREBBP, suppressing the transcriptional activation of β-catenin target genes [133]. Three trials have been evaluating PRI-724, two of which were terminated or withdrawn because of low enrollment or a drug supply issue (Table 2). A phase I trial evaluating the best dosage of PRI-724 revealed grade 2 AEs, including diarrhea, bilirubin elevation, hypophosphatemia, nausea, fatigue, anorexia, thrombocytopenia, and alkaline phosphatase elevation [52]. Another phase I trial evaluating the best dosage of PRI-724 combined with gemcitabine as second-line therapy for advanced pancreatic cancer revealed grade ≥ 3 AEs, including abdominal pain, neutropenia, anemia, fatigue, and alkaline phosphatase elevation [53]. The inhibitors of EP300, PYGO, and BCL9 (IQ-1, pyrvinium, and carnosic acid, respectively) have been evaluated in preclinical studies (Table 3) [117,134,135]. In addition, SM08502, a CDC-like kinase (CLK) inhibitor that blocks the phosphorylation of serine/arginine-rich splicing factors and consequently disrupts spliceosome activity, has been shown to inhibit Wnt signaling in preclinical models [136–138]. A phase I trial evaluating SM08502 for advanced GI cancers is ongoing (Table 2).

9. Caveats in Targeting Wnt Signaling

9.1. Targeting Core Components of Wnt Signaling

The major caveat in Wnt targeting strategies is their detrimental side effects on normal cells in which Wnt signaling plays pivotal roles in tissue homeostasis and regeneration [3–5]. For example, intestinal stem cells replenish the intestinal epithelium every 3 to 4 days; this is tightly regulated by constitutively active Wnt signaling in the crypt bottom [139,140]. Inhibiting Wnt signaling disrupts intestinal homeostasis and induces the severe loss of the crypt-villi structure. Similarly, upon Wnt blockade, tissue homeostasis disruption also takes place in hair follicles, the stomach, and the hematopoietic system, where Wnt signaling is indispensable for the maintenance of stem cells and their niches [141–143]. Indeed, the treatment of the FZD inhibitor (vanctumab) and antagonist (ipafircept) leads to side effects, including tiredness, diarrhea, vomiting, constipation, bone metabolism disorders, and abdominal pain [36,54]. Wnt signaling is also required for tissue homeostasis and regeneration in the lungs, liver, skin, and pancreas [3–5]. Therefore, Wnt signaling targeting strategies need to be
meticulously designed and evaluated on the basis of their specificity and efficacy, which is discussed in the next section.

9.2. Targeting Upstream vs. Downstream

Targeting the downstream effectors of Wnt signaling, e.g., β-catenin and TCF/LEF, might maximize Wnt signaling inhibition on the basis of signaling convergence into downstream gene regulation. However, targeting downstream Wnt signaling might also generate severe side effects by disrupting Wnt signaling in normal tissues. Conversely, targeting the upstream molecules of Wnt signaling, e.g., ligands and receptors, was initially considered ineffectual in cancer cells carrying mutations in Wnt signaling downstream (i.e., APC and β-catenin/CTNNB1) [93]. Intriguingly, accumulating evidence suggests that targeting Wnt signaling upstream is also effective independent of Wnt signaling downstream mutations. This evolving concept, the “β-catenin paradox”, is discussed below.

10. Evolving Views in Targeting Wnt Signaling

10.1. Cancer- and Tissue-Specific Wnt Signaling Targeting

Targeting cancer type- or tissue-specific Wnt signaling components or modulators may overcome the side effects of Wnt signaling blockade on normal tissues. For instance, specifically targeting the constitutively active form of β-catenin mutants may be ideal. A recent study found that small-molecule enhancers of mutant β-catenin and its E3 ligase (β-TrCP) interaction potentiate the ubiquitination-mediated degradation of mutant β-catenin [119], suggesting one possible approach to targeting the mutant form of β-catenin.

There are also several promising preclinical and clinical studies evaluating antibodies against RSPOs and LGRs, Wnt signaling amplifiers [42]. Since RSPOs and LGRs are differently expressed in different tissues and cancers [144,145], targeting them might diminish normal tissue damage. LGR5 has been suggested as a cancer stem cell marker [146,147], and targeting LGR5+ cells with anti-LGR5 antibody–drug conjugates suppressed tumor growth and metastasis in a preclinical model [145,148]. Anti-LGR5 therapy and anti-RSPO3 (rosmantuzumab) are currently being evaluated in phase I trials for the treatment of metastatic CRC (NCT02726334 and NCT02005315) (Table 2). RSPO3-LGR4-maintained Wnt signaling is essential for the stemness of acute myeloid leukemia, and the clinical-grade anti-RSPO3 antibody eradicated leukemia stem cells [149], which might be effective in GI cancer. The results of these studies indicate that blockage of cancer- or tissue-specific Wnt signaling components or regulators are viable options for GI cancer treatment.

10.2. Efficacy and Combination Therapy

An alternative method of overcoming limitations in Wnt signaling targeting strategies is to identify a safe dose that is highly effective but does not disrupt normal physiologic processes. A specific dose of LGK794 had lower severity of side effects with effective pharmacologic outcomes in a phase I clinical trial [7]. It is also noteworthy that different tissues showed different levels of Wnt signaling threshold in vivo [150], supporting the theory that localizing treatment is an alternative strategy to avoid toxicity and side effects.

In general, combination therapy is considered to result in more AEs. However, it does not always induce more AEs than does monotherapy. The incidences and degrees of AEs depend on various factors, such as the doses of single drugs, the timing of administration, the period of treatment, the supportive treatment, and the heterogeneity of the patients themselves. Thus, certain drug dose combinations may be more effective, with fewer AEs. Furthermore, monotherapy targeting one pathway does not guarantee complete anticancer activity because of multiple crosstalks and compensations by other signaling pathways. Although its efficacy may be counterbalanced by correspondingly increased toxicity, combination therapy that simultaneously targets several pathways might be more efficient.
In addition, combination therapy is the most common approach to achieving survival benefits in clinical practice, and most promising phase III Wnt targeting trials use combination therapy. ICG-001 and PRI-724 inhibit Wnt target gene expression by antagonizing CBP, a β-catenin coactivator [133,151]. PRI-724 was effective in a phase I clinical trial of PDAC when used in combination with gemcitabine (NCT01764477). Other cases include the combination of anti-FZD antibody with chemotherapy. Vantictumab (OMP-18R5) resulted in promising outcomes in the preclinical setting [152,153] and is currently being evaluated in phase I clinical trials for multiple cancers in combination with paclitaxel [154]. Ipafriccept (OMP-54F28/FZD8-Fc) is being evaluated in a phase I clinical trial to treat advanced pancreatic cancer in combination with nab-paclitaxel and gemcitabine [36]. Although antibodies against pan-Wnts or pan-FZD were not tissue-specific, their combination in advanced solid tumors had promising effects [36,154]. In addition, as a neoadjuvant therapy, Foxy-5 is currently being evaluated in phase II trials for colon cancer, as described above (NCT03883802).

10.3. β-Catenin Paradox

The β-catenin paradox was introduced on the basis of heterogeneous Wnt signaling activity in CRC cells, carrying homogenous genetic alterations in APC or β-catenin/CTNNB1 [155]. This observation was followed by discoveries of several Wnt signaling regulators and multiple crosstalks of Wnt/β-catenin signaling with MAPK and PI3K pathways [156–165]. Additionally, accumulating evidence suggests that the blockade of Wnt signaling upstream molecules suppresses tumor growth despite the presence of oncogenic mutations in Wnt signaling components [96,108,116,152,166,167], demonstrating the existence of additional regulatory modules in Wnt signaling, independent of genetic alterations. Additionally, truncated mutant APC remains partially functional to induce β-catenin protein degradation [116,167]. Moreover, the blockade of WNTs/RSPOs inhibits the growth of tumor cells that harbor APC mutations [96,116]. In line with this, Tankyrase inhibitor-stabilized AXIN protein suppresses the proliferation of CRC cells that carry constitutively active mutations in β-catenin or APC [108,110]. A recent gastric cancer mouse model study also revealed that vantictumab, the pan-FZD inhibitor, inhibits gastric adenoma growth independently of APC mutations [152]. Therefore, molecular targeting of the upstream molecules of APC and β-catenin might be promising in Wnt/β-catenin signaling-associated cancer.

10.4. Generalization of Wnt Targeting Therapy

Aberrant Wnt signaling is crucial for the potential clonal source of tumor cells and is considered an environmental and metastatic niche for tumor progression. Indeed, LGR5+ colon cancer cells are required for the formation of metastatic colonization in the liver [146]. A study using patient-derived pancreatic organoids revealed differing Wnt-niche dependency among organoids [168]. Furthermore, in a recent study of lung cancers that barely harbor Wnt mutations, Wnt signaling was shown to be required for lung cancer progression as a niche factor in a mouse lung adenocarcinoma model [169]. In that context, Wnt targeting by porcupine inhibitor, WNT794 (LGK794), revealed the suppression of lung tumor progression [169]. These results suggest that Wnt targeting therapy can be generalized to various types of non-Wnt-mutated cancers in which Wnt signaling has tumor-promoting or metastatic roles.

11. New Candidates for Targeting Wnt Signaling in GI Cancers

Several cancer-specific Wnt signaling regulators were identified in GI cancers. Amplification of USP21 deubiquitinase promotes pancreatic cancer cell growth and stemness via Wnt/β-catenin signaling [170]. RNF6, a CRC-upregulated E3 ligase, promotes CRC cell growth through the degradation of Tele3, a transcriptional repressor of the β-catenin/TCF4 complex [171]. Another deubiquitinase USP7 serves as a tumor-specific Wnt activator in APC-mutated CRC by promoting β-catenin deubiquitination [172]. Transcriptional coactivators of β-catenin, BCL9 and BCL9l, redundantly
demonstrated CRC-specific upregulation, and their loss suppressed intestinal tumorigenesis in a mouse model [173]. BCL9 and BCL9l inhibitors were recently developed [135,174,175]. Targeting BCL9 and BCL9l has been suggested as a therapeutic approach to CRC-specific treatment. FZD5 mainly expressed in RNF43 mutated tumor cells was proposed as a molecular target for pancreatic cancer treatment [68]. Given that gut-specific knockout of FZD5 is feasible in the mouse models [176,177], it is likely that targeting of FZD5 can be used in RNF43 mutated intestinal or gastric tumors. In addition, CRC-upregulated PAF/KIAA0101 hyperactivates Wnt/β-catenin signaling and accelerates tumorigenesis in vitro and in vivo [178,179]. As an amplifier of Wnt signaling, TMEM9 hyperactivates β-catenin via APC degradation to promote intestinal and hepatic tumorigenesis [116,166]. Of note, germline deletion of Tmem9 or Paf did not display any discernible phenotypes, suggests that blockade of cancer-related Wnt signaling activators or amplifiers minimizes side effects in Wnt signaling targeting approaches.

Additionally, recent technological advances in organoids made it feasible to perform high-throughput chemical screening (clinical drugs or drug library) and genetic screening (gene knock-out or knock-down) of tumor organoids [180–182]. Moreover, patient-derived organoids become valuable resources to identify most effective drug(s) for precision medicine including pharmacogenomics [183–185]. Therefore, with the emergence of such new technology, it is anticipated that novel tumor-specific and druggable vulnerabilities related to Wnt signaling hyperactivation will be identified.

12. Conclusions

To date, many studies have reported the marked impact of molecular targeting of Wnt signaling on tumor suppression in preclinical settings. Despite the ongoing clinical trials, it is still imperative to overcome recurring pitfalls—catastrophic adverse effects on tissue homeostasis and regeneration. Like the sword of Damocles, targeting Wnt signaling poses a high risk but has significant potential in cancer therapy. With evolving concepts in Wnt signaling deregulation and manipulation, new and improved approaches, including molecular targeting of upstream signaling modules or cancer-specific regulators and combination therapy, are expected to open a new window of opportunity in the treatment of Wnt signaling-associated cancer.

Author Contributions: M.J.K., Y.H., and J.-I.P. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by grants to the Cancer Prevention and Research Institute of Texas (RP140563 and RP200315 to J.-I.P.), the National Institutes of Health (2R01 CA193297 to J.-I.P.), the Department of Defense Peer Reviewed Cancer Research Program (CA140572 to J.-I.P.), an Institutional Research Grant (MD Anderson to J.-I.P.), a Specialized Program of Research Excellence (SPORE) grant in endometrial cancer (P50 CA83639), and an ROSI Seed Award (00057597 to M.K.J.).

Acknowledgments: We apologize for all of the studies we were not able to cite because of space limitations.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Nusse, R.; Varmus, H.E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982, 31, 99–109. [CrossRef]
2. Nusslein-Volhard, C.; Wieschaus, E. Mutations affecting segment number and polarity in Drosophila. Nature 1980, 287, 795–801. [CrossRef] [PubMed]
3. Steinhart, Z.; Angers, S. Wnt signaling in development and tissue homeostasis. Development 2018, 145, dev146589. [CrossRef] [PubMed]
4. Clevers, H.; Loh, K.M.; Nusse, R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 2014, 346, 1248012. [CrossRef]
5. Logan, C.Y.; Nusse, R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 2004, 20, 781–810. [CrossRef]
6. Nusse, R. Wnt signaling in disease and in development. Cell Res. 2005, 15, 28–32. [CrossRef]
7. Kahn, M. Can we safely target the WNT pathway? Nat. Rev. Drug Discov. **2014**, *13*, 513–532. [CrossRef]
8. Anastas, J.N.; Moon, R.T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer **2013**, *13*, 11–26. [CrossRef]
9. Jung, Y.S.; Park, J.I. Wnt signaling in cancer: Therapeutic targeting of Wnt signaling beyond beta-catenin and the destruction complex. *Exp. Mol. Med.* **2020**, *52*, 183–191. [CrossRef]
10. Niehrs, C. The complex world of WNT receptor signalling. *Nat. Rev. Mol. Cell Biol.* **2012**, *13*, 767–779. [CrossRef]
11. Li, V.S.; Ng, S.S.; Boersema, P.J.; Low, T.Y.; Karthaus, W.R.; Gerlach, J.P.; Mohammed, S.; Heck, A.J.; Maurice, M.M.; Mahmoudi, T.; et al. Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. *Cell 2012*, *149*, 1245–1256. [CrossRef] [PubMed]
12. Papkoff, J.; Brown, A.M.; Varmus, H.E. The int-1 proto-oncogene products are glycoproteins that appear to enter the secretory pathway. *Mol. Cell Biol.* **1987**, *7*, 3978–3984. [CrossRef] [PubMed]
13. Grumolato, L.; Liu, G.; Mong, P.; Mudbhary, R.; Biswas, R.; Arroyave, R.; Vijayakumar, S.; Economides, A.N.; Aaronson, S.A. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. *Genes Dev.* **2010**, *24*, 2517–2530. [CrossRef] [PubMed]
14. Gao, Z.H.; Seeling, J.M.; Hill, V.; Yochum, A.; Virshup, D.M. Casein kinase I phosphorylates and destabilizes the beta-catenin degradation complex. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 1182–1187. [CrossRef] [PubMed]
15. Ha, N.C.; Tonozuka, T.; Stamos, J.L.; Choi, H.J.; Weis, W.I. Mechanism of phosphorylation-dependent binding of APC to beta-catenin and its role in beta-catenin degradation. *Mol. Cell 2004*, *15*, 511–521. [CrossRef]
16. Liu, C.; Li, Y.; Semenov, M.; Han, C.; Baeg, G.-H.; Tan, Y.; Zhang, Z.; Lin, X.; He, X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. *Cell 2002*, *108*, 837–847. [CrossRef]
17. Stamos, J.L.; Weis, W.I. The beta-catenin destruction complex. *Cold Spring Harb. Perspect. Biol.* **2013**, *5*, a007896. [CrossRef]
18. He, X.; Semenov, M.; Tamai, K.; Zeng, X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: Arrows point the way. *Development 2003*, *131*, 1663–1677. [CrossRef]
19. Kishida, S.; Yamamoto, H.; Hino, S.; Ikeda, S.; Kishida, M.; Kikuchi, A. DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability. *Mol. Cell Biol.* **1999**, *19*, 4414–4422. [CrossRef]
20. Brunner, E.; Peter, O.; Schweizer, L.; Basler, K. Pangolin encodes a Lef-1 homologue that acts downstream of Armadillo to transduce the Wingless signal in Drosophila. *Nature 1997*, *385*, 829–833. [CrossRef]
21. van de Wetering, M.; Cavallo, R.; Dooijes, D.; van Beest, M.; van Es, J.; Loureiro, J.; Ypma, A.; Hursch, D.; Jones, T.; Beijovec, A.; et al. Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. *Cell 1997*, *88*, 789–799. [CrossRef]
22. Takemaru, K.I.; Moon, R.T. The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. *J. Cell Biol.* **2000**, *149*, 249–254. [CrossRef]
23. Hecht, A.; Vleminkx, K.; Stemmler, M.P.; van Roy, F.; Kemler, R. The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. *EMBO J.* **2000**, *19*, 1839–1850. [CrossRef] [PubMed]
24. Kikuchi, A.; Yamamoto, H.; Sato, A.; Matsumoto, S. New insights into the mechanism of Wnt signaling pathway activation. *Int. Rev. Cell Mol. Biol.* **2011**, *291*, 21–71. [PubMed]
25. Simons, M.; Mlodzik, M. Planar cell polarity signaling: From fly development to human disease. *Annu. Rev. Genet.* **2008**, *42*, 517–540. [CrossRef] [PubMed]
26. De, A. Wnt/Ca²⁺ signaling pathway: A brief overview. *Acta Biochim. Biophys. Sin.* **2011**, *43*, 745–756. [CrossRef] [PubMed]
27. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature 2012*, *487*, 330–337. [CrossRef]
28. Rowan, A.J.; Lamllum, H.; Ilyas, M.; Wheeler, J.; Straub, J.; Papadopoulou, A.; Bicknell, D.; Bodmer, W.F.; Tomlinson, I.P. APC mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits”. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 3352–3357. [CrossRef]
29. Russell, J.O.; Monga, S.P. Wnt/beta-catenin signaling in liver development, homeostasis, and pathobiology. *Annu. Rev. Pathol.* **2018**, *13*, 351–378. [CrossRef]
30. Khalaf, A.M.; Fuentes, D.; Morshid, A.I.; Burke, M.R.; Kaseb, A.O.; Hassan, M.; Hazel, J.D.; Elsayes, K.M. Role of Wnt/beta-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. *J. Hepatocell. Carcinoma* **2018**, *5*, 61–73. [CrossRef]
31. Merle, P.; de la Monte, S.; Kim, M.; Herrmann, M.; Tanaka, S.; Von Dem Bussche, A.; Kew, M.C.; Trepo, C.; Wands, J.R. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. *Gastroenterology* **2004**, *127*, 1110–1122. [CrossRef]

32. Waddell, N.; Pajic, M.; Patch, A.M.; Chang, D.K.; Kassahn, K.S.; Bailey, P.; Johns, A.L.; Miller, D.; Nones, K.; Quek, K.; et al. Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature* **2015**, *518*, 495–501. [CrossRef]

33. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* **2014**, *513*, 202–209. [CrossRef] [PubMed]

34. Ng, M.; Tan, D.S.; Subbiah, V.; Weekes, C.D.; Teneggi, V.; Diermayr, V.; Ethirajulu, K.; Yeo, P.; Chen, D.; Blanchard, S. First-in-human phase I study of ETC-159 an oral PORCN inhibitor in patients with advanced solid tumours. *Am. Soc. Clin. Oncol.* **2017**, *35*. [CrossRef]

35. Pintova, S.; Dharmupari, S.; Moshier, E.; Zubizarreta, N.; Ang, C.; Holcombe, R.F. Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: Phase II/II pilot study. *Cancer Chemother. Pharmacol.* **2019**, *84*, 591–598. [CrossRef] [PubMed]

36. Jimeno, A.; Gordon, M.; Chugh, R.; Messersmith, W.; Mendelson, D.; Dupont, J.; Stagg, R.; Kapoun, A.M.; Xu, L.; Utamasingh, S.; et al. A first-in-human phase I study of the anticancer stem cell agent ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* **2017**, *23*, 7490–7497. [CrossRef] [PubMed]

37. Dotan, E.; Cardin, D.B.; Lenz, H.J.; Messersmith, W.A.; O’Neil, B.; Cohen, S.J.; Denlinger, C.S.; Shahda, S.; Kapoun, A.M.; Brachmann, R.K.; et al. Phase Ib study of WNT inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (mPC). *Am. Soc. Clin. Oncol.* **2019**, *37*. [CrossRef]

38. Vermorken, J.; Cervantes, A.; Morsing, P.; Johansson, K.; Andersson, T.; Roest, N.L.; Gullbo, J.; Salazar, R. P-133 A randomized, multicenter, open-label controlled phase 2 trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer. *Ann. Oncol.* **2016**, *27* (Suppl. S4). [CrossRef]

39. Davis, S.L.; Cardin, D.B.; Shahda, S.; Lenz, H.J.; Dotan, E.; O’Neil, B.H.; Kapoun, A.M.; Stagg, R.J.; Berlin, J.; Messersmith, W.A.; et al. A phase 1b dose escalation study of Wnt pathway inhibitor vartanictubam in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. *Investig. New Drugs* **2019**, *38*, 821–830. [CrossRef]

40. Ryan, D.; Murphy, J.; Mahalingam, D.; Strickler, J.; Stein, S.; Sirad, C.; Landau, S.; Bendell, J. PD-016 Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ). *Ann. Oncol.* **2016**, *27* (Suppl. S2), ii108. [CrossRef]

41. Eads, J.R.; Goyal, L.; Stein, S.; El-Khoueiry, A.B.; Manji, G.A.; Abrams, T.A.; Landau, S.B.; Sirad, C.A. Phase I study of DKN-01, an anti-DKK1 antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer. *J. Clin. Oncol.* **2016**, *34* (Suppl. S15), e15603. [CrossRef]

42. Bendell, J.; Eckhardt, G.; Hochster, H.; Morris, V.; Strickler, J.; Kapoun, A.; Wang, M.; Xu, L.; McGuire, K.; Dupont, J. Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC). *Eur. J. Cancer* **2016**, *69* (Suppl. 1), S29–S30. [CrossRef]

43. Burock, S.; Daum, S.; Tröger, H.; Kim, T.D.; Krüger, S.; Rieke, D.T.; Ochsnerreither, S.; Welter, K.; Herrmann, P.; Sleegers, A. Niclosamide a new chemotherapy agent? Pharmacokinetics of the potential anticancer drug in a patient cohort of the NIKOLO trial. *Am. Soc. Clin. Oncol.* **2018**, *36*, e14536. [CrossRef]

44. Molenaar, R.J.; Coelen, R.J.S.; Khursheed, M.; Ho, E.; Caan, M.W.A.; van Linde, M.E.; Kouwenhoven, M.; Bramer, J.A.M.; Bovee, J.; Mathot, R.A.; et al. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours. *BMJ Open.* **2017**, *7*, e014961. [CrossRef] [PubMed]

45. Mahalingam, D.; Mita, M.; Sarantopoulos, J.; Wood, L.; Amaravadi, R.K.; Davis, L.E.; Mita, A.C.; Curiel, T.J.; Espitia, C.M.; Nawrocki, S.T.; et al. Combined autophagy and HDAC inhibition: A phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. *Autophagy* **2014**, *10*, 1403–1414. [CrossRef]
46. Boone, B.A.; Bahary, N.; Zureikat, A.H.; Moser, A.J.; Normolle, D.P.; Wu, W.C.; Singhi, A.D.; Bao, P.; Bartlett, D.L.; Liotta, L.A.; et al. Safety and biologic response of pre-operative autophagy inhibition in combination with gemcitabine in patients with pancreatic adenocarcinoma. *Ann. Surg. Oncol.* 2015, 22, 4402–4410. [CrossRef]

47. Loaiza-Bonilla, A.; O’Hara, M.H.; Redlinger, M.; Damjanov, N.; Teitelbaum, U.R.; Vasilevskaia, I.; Rosen, M.A.; Heitjan, D.F.; Amaravadi, R.K.; O’Dwyer, P.J. Phase II trial of autophagy inhibition using hydroxychloroquine (HCQ) with FOLFOX/bevacizumab in the first-line treatment of advanced colorectal cancer. *J. Clin. Oncol.* 2015, 33, 3614. [CrossRef]

48. Wolpin, B.M.; Rubinson, D.A.; Wang, X.; Chan, J.A.; Cleary, J.M.; Enzinger, P.C.; Fuchs, C.S.; McCleary, N.J.; Meyerhardt, J.A.; Ng, K.; et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. *Oncoologist* 2014, 19, 637–648. [CrossRef]

49. Hong, T.S.; Wo, J.Y.-L.; Jiang, W.; Yeap, B.Y.; Clark, J.W.; Ryan, D.P.; Blaszkowsky, L.S.; Drapek, L.C.; Mamon, H.J.; Murphy, J.E.; et al. Phase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC). *J. Clin. Oncol.* 2017, 35, 4118. [CrossRef]

50. Karasic, T.B.; O’Hara, M.H.; Loaiza-Bonilla, A.; Reiss, K.A.; Teitelbaum, U.R.; Borazanci, E.; De Jesus-Acosta, A.; Redlinger, C.; Burrell, J.A.; Laheru, D.A.; et al. Effect of gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: A phase 2 randomized clinical trial. *JAMA Oncol.* 2019, 5, 993–998. [CrossRef]

51. Arora, S.P.; Tenny, L.L.; Sarantopoulos, J.; Morris, J.L.; Longoria, L.; Liu, Q.; Michalek, J.; Mahalingam, D. Modulation of autophagy: A Phase II study of vorinostat (VOR) plus hydroxychloroquine (HCQ) vs regorafenib (RGF) in chemo-refractory metastatic colorectal cancer (mCRC). *J. Clin. Oncol.* 2019, 37, 3551. [CrossRef]

52. El-Khoueiry, A.B.; Ning, Y.; Yang, D.; Cole, S.; Kahn, M.; Zoghbi, M.; Berg, J.; Fujimori, M.; Inada, T.; Kouji, H. A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. *Am. Soc. Clin. Oncol.* 2013, 31, 2501. [CrossRef]

53. Ko, A.H.; Chiorean, E.G.; Kwak, E.L.; Lenz, H.-J.; Nadler, P.I.; Wood, D.L.; Fujimori, M.; Inada, T.; Kouji, H.; McWilliams, R.R. Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. *Am. Soc. Clin. Oncol.* 2016, 34, e15721. [CrossRef]

54. Fischer, M.M.; Cancilla, B.; Yeung, V.P.; Cattaruzza, F.; Chartier, C.; Murriel, C.L.; Cain, J.; Tam, R.; Cheng, C.Y.; Evans, J.W.; et al. WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. *Sci. Adv.* 2017, 3, e1700990. [CrossRef]

55. Lopez-Rios, J.; Esteve, P.; Ruiz, J.M.; Bovolenta, P. The Netrin-related domain of Sfrp1 interacts with Wnt ligands and antagonizes their activity in the anterior neural plate. *Cell. Signal.* 2018, 39, 16. [CrossRef]

56. Bu, Q.; Li, Z.; Zhang, J.; Xu, F.; Liu, J.; Liu, H. The crystal structure of full-length Sizzled from Xenopus laevis yields insights into Wnt-antagonistic function of secreted Frizzled-related proteins. *J. Biol. Chem.* 2017, 292, 16055–16069. [CrossRef]

57. Agostino, M.; Pohl, S.O.; Dharmarajan, A. Structure-based prediction of Wnt binding affinities for Frizzled-type cysteine-rich domains. *J. Biol. Chem.* 2017, 292, 11218–11229. [CrossRef]

58. Xavier, C.P.; Melikova, M.; Chuman, Y.; Uren, A.; Baljinnym, B.; Rubin, J.S. Secreted Frizzled-related protein potentiation versus inhibition of Wnt3a/beta-catenin signaling. *Cell. Signal.* 2014, 26, 94–101. [CrossRef]

59. Liang, C.J.; Wang, Z.W.; Chang, Y.W.; Lee, K.C.; Lin, W.H.; Lee, J.L. SFRPs are biphasic modulators of Wnt-signaling-elicited cancer stem cell properties beyond extracellular control. *Cell Rep.* 2019, 28, 1511–1525.e5. [CrossRef]

60. Malinauskas, T.; Ariescu, A.R.; Lu, W.; Siebold, C.; Jones, E.Y. Modular mechanism of Wnt signaling inhibition by Wnt inhibitory factor 1. *Nat. Struct. Mol. Biol.* 2011, 18, 886–893. [CrossRef]

61. Piccolo, S.; Agius, E.; Leyns, L.; Bhattacharyya, S.; Grunz, H.; Bouwmeester, T.; De Robertis, E.M. The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals. *Nature* 1999, 397, 707–710. [CrossRef] [PubMed]

62. Rios-Esteves, J.; Haugen, B.; Resh, M.D. Identification of key residues and regions important for porcupine-mediated Wnt acylation. *J. Biol. Chem.* 2014, 289, 17009–17019. [CrossRef] [PubMed]
Cancers 2020, 12, 3638

63. Yu, J.; Chia, J.; Canning, C.A.; Jones, C.M.; Bard, F.A.; Virshup, D.M. WLS retrograde transport to the endoplasmic reticulum during Wnt secretion. Dev. Cell 2014, 29, 277–291. [CrossRef] [PubMed]

64. Suciu, R.M.; Cognetta, A.B.; Potter, Z.E.; Cravatt, B.F. Selective irreversible inhibitors of the Wnt-deacetylating enzyme NOTUM developed by activity-based protein profiling. ACS Med. Chem. Lett. 2018, 9, 563–568. [CrossRef]

65. Moverare-Skrtic, S.; Nilsson, K.H.; Henning, P.; Funck-Brentano, T.; Nethander, M.; Rivadeneira, F.; Nunes, G.C.; Koskela, A.; Tuukkanen, J.; Tuckermann, J.; et al. Osteoblast-derived NOTUM reduces cortical bone mass in mice and the NOTUM locus is associated with bone mineral density in humans. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2019, 33, 11163–11179. [CrossRef]

66. Zhang, X.; Abreu, J.G.; Yokota, C.; MacDonald, B.T.; Singh, S.; Coburn, K.L.; Cheong, S.M.; Zhang, M.M.; Ye, Q.Z.; Hang, H.C.; et al. Tiki1 is required for head formation via Wnt cleavage-oxidation and inactivation. Cell 2012, 149, 1565–1577. [CrossRef]

67. Zhang, X.; MacDonald, B.T.; Gao, H.; Shamashkin, M.; Coyle, A.J.; Martinez, R.V.; He, X. Characterization of Tiki, a New Family of Wnt-specific Metalloproteases. J. Biol. Chem. 2016, 291, 2435–2443. [CrossRef]

68. Steinhart, Z.; Pavlovic, Z.; Chandrashekhar, M.; Hart, T.; Wang, X.; Zhang, X.; Robitaille, M.; Brown, K.R.; Jaksani, S.; Overmeer, R.; et al. Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors. Nat. Med. 2017, 23, 60–68. [CrossRef]

69. Slusarski, D.C.; Yang-Snyder, J.; Busa, W.B.; Moon, R.T. Modulation of embryonic intracellular Ca²⁺ signaling by Wnt-5α. Dev. Biol. 1997, 182, 114–120. [CrossRef]

70. Murphy, L.L.; Hughes, C.C. Endothelial cells stimulate T cell NFAT nuclear translocation in the presence of cyclosporin A: Involvement of the wnt/glycogen synthase kinase-3 beta pathway. J. Immunol. 2002, 169, 3717–3725. [CrossRef]

71. Sheldahl, L.C.; Park, M.; Malbon, C.C.; Moon, R.T. Protein kinase C is differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent manner. Curr. Biol. CB 1999, 9, 695–698. [CrossRef]

72. Kühl, M.; Sheldahl, L.C.; Malbon, C.C.; Moon, R.T. Ca²⁺/calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in Xenopus. J. Biol. Chem. 2000, 275, 12701–12711. [CrossRef] [PubMed]

73. Mikels, A.J.; Nusse, R. Purified Wnt5α protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006, 4, e115. [CrossRef] [PubMed]

74. Sato, A.; Yamamoto, H.; Sakane, H.; Koyama, H.; Kikuchi, A. Wnt5a regulates distinct signalling pathways by binding to Frizzled2. EMBO J. 2010, 29, 41–54. [CrossRef]

75. Saisholm, A.; Tuomela, J.; Rosenkvist, J.; Dejmek, J.; Harkonen, P.; Andersson, T. The Wnt-5α-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2008, 14, 6556–6563. [CrossRef]

76. Saisholm, A.; Leandersson, K.; Dejmek, J.; Nielsen, C.K.; Villoutreix, B.O.; Andersson, T. A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. J. Biol. Chem. 2006, 281, 2740–2749. [CrossRef]

77. Jönsson, M.; Andersson, T. Repression of Wnt-5α impairs DDR1 phosphorylation and modifies adhesion and migration of mammary cells. J. Cell Sci. 2001, 114 Pt 11, 2043–2053.

78. Glinka, A.; Wu, W.; Delius, H.; Monaghan, A.P.; Blumenstock, C.; Niehrs, C.J.N. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998, 391, 357–362. [CrossRef]

79. Niehrs, C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 2006, 25, 7469–7481. [CrossRef]

80. Yu, B.; Yang, X.; Xu, Y.; Yao, G.; Shu, H.; Lin, B.; Hood, L.; Wang, H.; Yang, S.; Gu, J.; et al. Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J. Hepatol. 2009, 50, 948–957. [CrossRef]

81. Xu, W.H.; Liu, Z.B.; Yang, C.; Qin, W.; Shao, Z.M. Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype. PLoS ONE 2012, 7, e37624. [CrossRef] [PubMed]

82. Shi, R.Y.; Yang, X.R.; Shen, Q.J.; Yang, L.X.; Xu, Y.; Qiu, S.J.; Sun, Y.F.; Zhang, X.; Wang, Z.; Zhu, K.; et al. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery. Cancer 2013, 119, 993–1003. [CrossRef] [PubMed]
Cancers 2020, 12, 3638

83. Chen, C.; Zhou, H.; Zhang, X.; Ma, X.; Liu, Z.; Liu, X. Elevated levels of Dickkopf-1 are associated with beta-catenin accumulation and poor prognosis in patients with chondrosarcoma. *PLoS ONE* 2014, 9, e105414.

84. Shi, Y.; Gong, H.L.; Zhou, L.; Tian, J.; Wang, Y. Dickkopf-1 is a novel prognostic biomarker for laryngeal squamous cell carcinoma. *Acta Otolaryngol.* 2014, 134, 753–759. [CrossRef]

85. Chen, W.; Zhang, Y.W.; Li, Y.; Zhang, J.W.; Zhang, T.; Fu, B.S.; Zhang, Q.; Jiang, N. Constitutive expression of Wnt/beta-catenin target genes promotes proliferation and invasion of liver cancer stem cells. *Mol. Med. Rep.* 2016, 13, 3466–3474. [CrossRef]

86. Zhuang, X.; Zhang, H.; Li, X.; Li, X.; Cong, M.; Peng, F.; Yu, J.; Zhang, X.; Yang, Q.; Hu, G. Differential effects on lung and bone metastasis of breast cancer by Wnt signaling inhibitor DKK1. *Nat. Cell Biol.* 2017, 19, 1274–1285. [CrossRef]

87. Caneparo, L.; Huang, Y.L.; Staudt, N.; Tada, M.; Ahrendt, R.; Kazanskaya, O.; Niehrs, C.; Houart, C. Dickkopf-1 is a novel prognostic biomarker for laryngeal squamous cell carcinoma. *Acta Otolaryngol.* 2014, 134, 753–759. [CrossRef]

88. Cha, S.W.; Tadjuidje, E.; Tao, Q.; Wylie, C.; Heasman, J. Wnt5a and Wnt11 interact in a maternal Dkk1-regulated fashion to activate both canonical and non-canonical signaling in Xenopus axis formation. *Development* 2008, 135, 3719–3729. [CrossRef]

89. Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Novotny, V.; Cote, J.R.; et al. RECIST 1.1. *Eur. J. Cancer* 2009, 45, 228–247. [CrossRef]

90. Yanagita, M.; Oka, M.; Watabe, T.; Iguchi, H.; Niida, A.; Takahashi, S.; Akiyama, T.; Miyazono, K.; Yanagisawa, M.; Sakurai, T. USA-1: A bone morphogenetic protein antagonist abundantly expressed in the kidney. *Biochem. Biophys. Res. Commun.* 2004, 316, 490–500. [CrossRef]

91. Itasaki, N.; Jones, C.M.; Mercurio, S.; Rowe, A.; Domingos, P.M.; Smith, J.C.; Krumlauf, R. Wise, a context-dependent activator and inhibitor of Wnt signalling. *Development* 2003, 130, 4295–4305. [CrossRef] [PubMed]

92. de Lau, W.; Peng, W.C.; Gros, P.; Clevers, H. The R-spondin/Lgr5/Rnf43 module: Regulator of Wnt signal strength. *Genes Dev.* 2014, 28, 305–316. [CrossRef] [PubMed]

93. Nusse, R.; Clevers, H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. *Cell* 2017, 169, 985–999. [CrossRef] [PubMed]

94. Seshagiri, S.; Stawiski, E.W.; Durinck, S.; Modrusan, Z.; Storm, E.E.; Conboy, C.B.; Chaudhuri, S.; Guan, Y.; Nusse, R.; Clevers, H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. *Cell* 2017, 169, 985–999. [CrossRef] [PubMed]

95. Koo, B.K.; Spit, M.; Jordens, I.; Low, T.Y.; Stange, D.E.; van de Wetering, M.; van Es, J.H.; Mohammed, S.; Heck, A.J.; Maurice, M.M.; et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. *Nature* 2012, 488, 665–669. [CrossRef] [PubMed]

96. Koo, B.K.; Spit, M.; Jordens, I.; Low, T.Y.; Stange, D.E.; van de Wetering, M.; van Es, J.H.; Mohammed, S.; Heck, A.J.; Maurice, M.M.; et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. *Nature* 2012, 488, 665–669. [CrossRef] [PubMed]

97. Inglis, D.J.; Licari, J.; Georgiou, K.R.; Wittweer, N.L.; Hamilton, R.W.; Beaumont, D.M.; Scherer, M.A.; Lavranos, T.C. Abstract 3910: Characterization of BNC101 a human specific monoclonal antibody targeting the GPCR LGR5. First-in-human evidence of target engagement. *Cancer Res.* 2018, 78 (Suppl. S13), 3910.

98. Osada, T.; Chen, M.; Yang, X.Y.; Spasojevic, I.; Vandeusen, J.B.; Hsu, D.; Clary, B.M.; Clay, T.M.; Chen, W.; Morse, M.A.; et al. Antihelminthic compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. *Cancer Res.* 2011, 71, 4172–4182. [CrossRef]

99. Chen, M.; Wang, J.; Lu, J.; Bond, M.C.; Ren, X.R.; Lyerly, H.K.; Barak, L.S.; Chen, W. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. *Biochemistry* 2009, 48, 10267–10274. [CrossRef]

100. Lu, W.; Lin, C.; Roberts, M.J.; Waud, W.R.; Piazza, G.A.; Li, Y. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LR6P degradation and inhibiting the Wnt/beta-catenin pathway. *PLoS ONE* 2011, 6, e29290. [CrossRef]

101. Wong, H.-C.; Bourdelas, A.; Krauss, A.; Lee, H.-J.; Shao, Y.; Wu, D.; Mlodzik, M.; Shi, D.-L.; Zheng, J. Direct binding of the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal region of Frizzled. *Mol. Cell* 2003, 12, 1251–1260. [CrossRef]
102. Fiedler, M.; Mendoza-Topaz, C.; Rutherford, T.J.; Mieszczanek, J.; Bienz, M. Dishevelled interacts with the DIX domain polymerization interface of Axin to interfere with its function in down-regulating beta-catenin. Proc. Natl. Acad. Sci. USA 2011, 108, 1937–1942. [CrossRef] [PubMed]

103. Grandy, D.; Shan, J.; Zhang, X.; Rao, S.; Akunuru, S.; Li, H.; Zhang, Y.; Alpatov, I.; Zhang, X.A.; Lang, R.A.; et al. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J. Biol. Chem. 2009, 284, 16256–16263. [CrossRef] [PubMed]

104. Fujii, N.; You, L.; Xu, Z.; Uematsu, K.; Shan, J.; He, B.; Mikami, I.; Edmondson, L.R.; Neale, G.; Zheng, J.; et al. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res. 2007, 67, 573–579. [CrossRef] [PubMed]

105. Shan, J.; Shi, D.L.; Wang, J.; Zheng, J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 2005, 44, 15495–15503. [CrossRef]

106. Zhang, Y.; Appleton, B.A.; Wiesmann, C.; Lau, T.; Costa, M.; Hannoush, R.N.; Sidhu, S.S. Inhibition of Wnt signaling by Dishevelled PDZ peptides. Nat. Chem. Biol. 2009, 5, 217–219. [CrossRef]

107. Riffell, J.L.; Lord, C.J.; Ashworth, A. Tankyrase-targeted therapeutics: Expanding opportunities in the PARP family. Nat. Rev. Drug Discov. 2012, 11, 923–936. [CrossRef]

108. Huang, S.M.; Mishina, Y.M.; Liu, S.; Cheung, A.; Stegmeier, F.; Michaud, G.A.; Charlat, O.; Wiellette, E.; Zhang, Y.; Wiessner, S.; et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2011, 461, 614–620. [CrossRef]

109. Huang, J.; Xiao, D.; Li, G.; Ma, J.; Chen, P.; Yuan, W.; Hou, F.; Ge, J.; Zhong, M.; Tang, Y.; et al. EphA2 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer cells. Oncogene 2014, 33, 2737–2747. [CrossRef]

110. Lau, T.; Chan, E.; Callow, M.; Waaler, J.; Boggs, J.; Blake, R.A.; Magnuson, S.; Sambrone, A.; Schutten, M.; Firestein, R.; et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. 2013, 73, 3132–3144. [CrossRef]

111. Martins-Neves, S.R.; Paiva-Oliveira, D.I.; Fontes-Ribeiro, C.; Bové, J.; Cleton-Jansen, A.M.; Gomes, C.M.F. IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft. Cancer Lett. 2018, 414, 1–15. [CrossRef] [PubMed]

112. Scarborough, H.A.; Helfrich, B.A.; Casás-Selves, M.; Schuller, A.G.; Grosskurth, S.E.; Kim, J.; Tan, A.C.; Chan, D.C.; Zhang, Z.; Zaberezhnyy, V.; et al. AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2017, 23, 1531–1541. [CrossRef] [PubMed]

113. Waaler, J.; Machon, O.; Tumova, L.; Dinh, H.; Korinek, V.; Wilson, S.R.; Paulsen, J.E.; Pedersen, N.M.; Eide, T.J.; Machonova, O.; et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 2012, 72, 2822–2832. [CrossRef] [PubMed]

114. Ji, L.; Jiang, B.; Jiang, X.; Charlat, O.; Chen, A.; Mickanin, C.; Bauer, A.; Xu, W.; Yan, X.; Cong, F. The SIAH E3 ubiquitin ligases promote Wnt/beta-catenin signaling through mediating Wnt-induced Axin degradation. Genes Dev. 2017, 31, 904–915. [CrossRef]

115. Ji, L.; Lu, B.; Zamponi, R.; Charlat, O.; Aversa, R.; Yang, Z.; Sigoillot, F.; Zhu, X.; Hu, T.; Reece-Hoyes, J.S.; et al. USP7 inhibits Wnt/beta-catenin signaling through promoting stabilization of Axin. Nat. Commun. 2019, 10, 4184. [CrossRef]

116. Jung, Y.S.; Jun, S.; Kim, M.J.; Lee, S.H.; Suh, H.N.; Lien, E.M.; Jung, H.Y.; Lee, S.; Zhang, J.; Yang, J.I.; et al. TMEFP3 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/beta-catenin signalling. Nat. Cell Biol. 2018, 20, 1421–1433. [CrossRef]

117. Thorne, C.A.; Hanson, A.J.; Schneider, J.; Tahinci, E.; Orton, D.; Cseleényi, C.S.; Jernigan, K.K.; Meyers, K.C.; Hang, B.I.; Waterson, A.G.; et al. Small-molecule inhibition of Wnt signalling through activation of casein kinase 1alpha. Nat. Chem. Biol. 2010, 6, 829–836. [CrossRef]

118. Hwang, S.Y.; Deng, X.; Byun, S.; Lee, C.; Lee, S.J.; Suh, H.; Zhang, J.; Kang, Q.; Zhang, T.; Westover, K.D.; et al. Direct targeting of beta-catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt/beta-catenin signaling. Cell Rep. 2016, 16, 28–36. [CrossRef]
Cancers 2020, 12, 3638

119. Simonetta, K.R.; Taygerly, J.; Boyle, K.; Basham, S.E.; Padovani, C.; Lou, Y.; Cummins, T.J.; Yung, S.L.; von Soly, S.K.; Kayser, F.; et al. Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction. *Nat. Commun.* 2019, 10, 1402. [CrossRef]

120. Goentoro, L.; Kirschner, M.W. Evidence that fold-change, and not absolute level, of beta-catenin dictates Wnt signaling. *Mol. Cell* 2009, 36, 872–884. [CrossRef]

121. Cadigan, K.M.; Waterman, M.L. TCF/LEFs and Wnt signaling in the nucleus. *Cold Spring Harb. Perspect. Biol.* 2012, 4, a007906. [CrossRef] [PubMed]

122. Gonsalves, F.C.; Klein, K.; Carson, B.B.; Katz, S.; Ekas, L.A.; Evans, S.; Nagourney, R.; Cardozo, T.; Brown, A.M.; DasGupta, R. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. *Proc. Natl. Acad. Sci. USA* 2011, 108, 5954–5963. [CrossRef] [PubMed]

123. Sukhdeo, K.; Mani, M.; Zhang, Y.; Dutta, J.; Yasui, H.; Rooney, M.D.; Carrasco, D.E.; Zheng, M.; He, H.; Tai, Y.T.; et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. *Proc. Natl. Acad. Sci. USA* 2007, 104, 7516–7521. [CrossRef] [PubMed]

124. Tian, W.; Han, X.; Yan, M.; Xu, Y.; Duggineni, S.; Lin, N.; Luo, G.; Li, Y.M.; Han, X.; Huang, Z.; et al. Structure-based discovery of a novel inhibitor targeting the beta-catenin/Tcf4 interaction. *Biochemistry* 2012, 51, 724–731. [CrossRef]

125. Mahmoudi, T.; Li, V.S.; Ng, S.S.; Taouatas, N.; Vries, R.G.; Mohammed, S.; Heck, A.J.; Clevers, H. The kinase TNIK is an essential activator of Wnt target genes. *EMBO J.* 2009, 28, 3329–3340. [CrossRef] [PubMed]

126. Masuda, M.; Uno, Y.; Obayashi, N.; Ohata, H.; Mimata, A.; Kuwamoto-Niino, M.; Moriyama, H.; Kashimoto, S.; Inoue, T.; Goto, N.; et al. TNIK inhibition abrogates colorectal cancer stemness. *Nat. Commun.* 2016, 7, 12586. [CrossRef]

127. Shitashige, M.; Satow, R.; Jigami, T.; Aoki, K.; Honda, K.; Shibata, T.; Ono, M.; Hirohashi, S.; Yamada, T. Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. *Cancer Res.* 2010, 70, 5024–5033. [CrossRef]

128. Lee, Y.; Jung, J.I.; Park, K.Y.; Kim, S.A.; Kim, J. Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells. *OncoTarget* 2017, 8, 41091–41101. [CrossRef]

129. Ishitani, T.; Ninomiya-Tsuji, J.; Nagai, S.; Nishita, M.; Meneghini, M.; Barker, N.; Waterman, M.; Bowerman, B.; Clevers, H.; Shibuya, H. The TAK1-NLK MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. *Nature* 1999, 399, 798–802. [CrossRef] [PubMed]

130. Ishitani, T.; Kishida, S.; Hyodo-Miura, J.; Ueno, N.; Yasuda, J.; Waterman, M.; Shibuya, H.; Moon, R.T.; Ninomiya-Tsuji, J.; Matsumoto, K. The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. *Mol. Cell Biol.* 2003, 23, 131–139. [CrossRef]

131. Hikasa, H.; Sokol, S.Y. Phosphorylation of TCF proteins by homeodomain-interacting protein kinase 2. *J. Biol. Chem.* 2011, 286, 12093–12100. [CrossRef] [PubMed]

132. Hikasa, H.; Ezan, J.; Itoh, K.; Li, X.; Klymkowsky, M.W.; Sokol, S.Y. Regulation of TCF3 by Wnt-dependent phosphorylation during vertebrate axis specification. *Dev. Cell* 2010, 19, 521–532. [CrossRef] [PubMed]

133. Emami, K.H.; Nguyen, C.; Ma, H.; Kim, D.H.; Jeong, K.W.; Eguchi, M.; Moon, R.T.; Teo, J.L.; Kim, H.Y.; Moon, S.H.; et al. A small molecule inhibitor of beta-catenin/CREB-binding protein [corrected]. *Proc. Natl. Acad. Sci. USA* 2004, 101, 12682–12687. [CrossRef] [PubMed]

134. Miyabayashi, T.; Teo, J.L.; Yamamoto, M.; McMillan, M.; Nguyen, C.; Kahn, M. Wnt/beta-catenin/CBP signaling maintains long-term murine embryonic stem cell pluripotency. *Proc. Natl. Acad. Sci. USA* 2007, 104, 5668–5673. [CrossRef] [PubMed]

135. de la Roche, M.; Rutherford, T.J.; Gupta, D.; Veprintsev, D.B.; Saxty, B.; Freund, S.M.; Bientz, M. An intrinsically labile alpha-helix abutting the BCL9-binding site of beta-catenin is required for its inhibition by carnosic acid. *Nat. Commun.* 2012, 3, 680. [CrossRef] [PubMed]

136. Tam, B.Y.; Chiu, K.; Chung, H.; Bossard, C.; Nguyen, J.D.; Creger, E.; Eastman, B.W.; Mak, C.C.; Ibanez, M.; Ghias, A.; et al. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. *Cancer Lett.* 2020, 473, 186–197. [CrossRef]

137. Bossard, C.; Chiu, K.; Chung, H.; Nguyen, J.D.; Creger, E.; Eastman, B.; Mak, C.C.; Do, L.; Cho, S.; KC, S. Effects of SM08502, a novel, oral small-molecule inhibitor of Wnt pathway signaling, on gene expression and antitumor activity in colorectal cancer (CRC) models. *Am. Soc. Clin. Oncol.* 2019, 37, e15185. [CrossRef]
138. Bossard, C.; Cruz, N.; Eastman, B.; Mak, C.-C.; Sunil, K.; Tam, B.; Bucci, G.; Stewart, J.; Phalen, T.; Cha, S. Abstract A02: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, downregulates the Wnt signaling pathway and demonstrates antitumor activity in pancreatic cancer cell lines and in vivo xenograft models. AACR 2019. [CrossRef]

139. Pinto, D.; Gregoriou, A.; Begthel, H.; Clevers, H. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. Genes Dev. 2003, 17, 1709–1713. [CrossRef]

140. Fevr, T.; Robine, S.; Louvard, D.; Huelsken, J. Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol. Cell Biol. 2007, 27, 7551–7559. [CrossRef]

141. Ito, M.; Yang, Z.; Andl, T.; Cui, C.; Kim, N.; Millar, S.E.; Cotsarelis, G. Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. Nature 2007, 447, 316–320. [CrossRef] [PubMed]

142. Duncan, A.W.; Rattis, F.M.; DiMascio, L.N.; Congdon, K.L.; Pazianos, G.; Zhao, C.; Yoon, K.; Cook, J.M.; Willert, K.; Gaiano, N.; et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat. Immunol. 2005, 6, 314–322. [CrossRef] [PubMed]

143. Schepers, A.; Clevers, H. Wnt signaling, stem cells, and cancer of the gastrointestinal tract. Cold Spring Harb. Perspect. Biol. 2012, 4, a007989. [CrossRef] [PubMed]

144. Barker, N.; Tan, S.; Clevers, H. Lgr proteins in epithelial stem cell biology. Development 2013, 140, 2484–2494. [CrossRef] [PubMed]

145. Junttila, M.R.; Mao, W.; Wang, X.; Wang, B.E.; Pham, T.; Flygare, J.; Yu, S.F.; Yee, S.; Goldenberg, D.; Fields, C.; et al. Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer. Sci. Transl. Med. 2015, 7, 314ra186. [CrossRef]

146. de Sousa e Melo, F.; Kurtova, A.V.; Harmess, J.M.; Kljavin, N.; Hoeck, J.D.; Hung, J.; Anderson, J.E.; Storm, E.E.; Modrusan, Z.; Koeppen, H.; et al. A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer. Nature 2017, 543, 676–680. [CrossRef]

147. Shimokawa, M.; Ohta, Y.; Nishikori, S.; Matano, M.; Takano, A.; Fujii, M.; Date, S.; Sugimoto, S.; Kanai, T.; Sato, T. Visualization and targeting of LGR5(+) human colon cancer stem cells. Nature 2017, 545, 187–192. [CrossRef]

148. Gong, X.; Azhdarinia, A.; Ghosh, S.C.; Xiong, W.; An, Z.; Liu, Q.; Carmon, K.S. LGR5-targeted antibody-drug conjugate eradicates gastrointestinal tumors and prevents recurrence. Mol. Cancer Ther. 2016, 15, 1580–1590. [CrossRef]

149. Salik, B.; Yi, H.; Hassan, N.; Santiappillai, N.; Vick, B.; Connerty, P.; Duly, A.; Trahair, T.; Woo, A.J.; Beck, D.; et al. Targeting RSPO3-LGR4 signaling for leukemia stem cell eradication in acute myeloid leukemia. Cancer 2020, 38, 263–278.e6. [CrossRef]

150. Buchert, M.; Athineos, D.; Abud, H.E.; Burke, Z.D.; Faux, M.C.; Samuels, M.S.; Jamrich, A.G.; Winbanks, C.E.; Newton, L.P.; Meniel, V.S.; et al. Genetic dissection of differential signaling threshold requirements for the Wnt/beta-catenin pathway in vivo. PLoS Genet. 2010, 6, e1000816. [CrossRef]

151. Lenz, H.J.; Kahn, M. Safely targeting cancer stem cells via selective catenin coactivator antagonism. Cancer Sci. 2014, 105, 1087–1092. [CrossRef] [PubMed]

152. Flanagan, D.J.; Barker, N.; Costanzo, N.S.D.; Mason, E.A.; Gurney, A.; Meniel, V.S.; Koushyar, S.; Austin, C.R.; Ernst, M.; Pearson, H.B.; et al. Frizzled-7 is required for Wnt signaling in gastric tumors with and without Apc mutations. Cancer Res. 2019, 79, 970–981. [CrossRef] [PubMed]

153. Gurney, A.; Axelrod, F.; Bond, C.J.; Chartier, C.; Donigan, L.; Fischer, M.; Chaudhari, A.; Ji, M.; Kapoun, A.M.; et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human cancers. Proc. Natl. Acad. Sci. USA 2012, 109, 11717–11722. [CrossRef] [PubMed]

154. Diamond, J.R.; Becerra, C.; Richards, D.; Mita, A.; Osborne, C.; O'Shaughnessy, J.; Zhang, C.; Henner, R.; Kapoun, A.M.; Xu, L.; et al. Phase I/II clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res. Treat. 2020, 184, 53–62. [CrossRef]

155. Fodde, R.; Tomlinson, I. Nuclear beta-catenin expression and Wnt signalling: In defence of the dogma. J. Pathol. 2010, 221, 239–241. [CrossRef]
157. Phelps, R.A.; Chidester, S.; Dehghanizadeh, S.; Phelps, J.; Sandoval, I.T.; Rai, K.; Broadbent, T.; Sarkar, S.; Burt, R.W.; Jones, D.A. A two-step model for colon adenoma initiation and progression caused by APC loss. *Cell* 2009, 137, 623–634. [CrossRef]

158. Janssen, K.P.; Alberci, P.; Fishti, H.; Gaspar, C.; Breukel, C.; Franken, P.; Rosty, C.; Abal, M.; El Marjou, F.; Smits, R.; et al. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. *Gastroenterology* 2006, 131, 1096–1109. [CrossRef]

159. Horst, D.; Chen, J.; Morikawa, T.; Ogino, S.; Kirchner, T.; Shivdasani, R.A. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. *Cancer Res.* 2012, 72, 1547–1556. [CrossRef]

160. Mzoughi, S.; Zhang, J.; Hequet, D.; Teo, S.X.; Fang, H.; Xing, Q.R.; Bezzi, M.; Seah, M.K.Y.; Ong, S.L.M.; Shin, E.M.; et al. PRDM15 safeguards naive pluripotency by transcriptionally regulating WNT and MAPK-ERK signaling. *Nat. Genet.* 2017, 49, 1354–1363. [CrossRef]

161. Jung, Y.S.; Jun, S.; Lee, S.H.; Sharma, A.; Park, J.I. Wnt2 complements Wnt/β-catenin signaling in colorectal cancer. *Oncotarget* 2015, 6, 37257–37268. [CrossRef][PubMed]

162. Tomar, V.S.; Patil, V.; Somasundaram, K. Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: Implications in glioma therapy. *Cell Biol. Toxicol.* 2020, 36, 273–278. [CrossRef][PubMed]

163. Prossomariti, A.; Piazzì, G.; Alquati, C.; Ricciardiello, L. Are Wnt dependent Wnt2b positive cells a common hallmark of pancreatic ductal adenocarcinoma? *Cell. Mol. Gastroenterol. Hepatol.* 2020, 10, 491–506. [CrossRef][PubMed]

164. Shorning, B.Y.; Dass, M.S.; Smalley, M.J.; Pearson, H.B. The PI3K-AKT-mTOR pathway and prostate cancer: At the crossroads of AR, MAPK, and WNT signaling. *Int. J. Mol. Sci.* 2020, 21, 4507. [CrossRef]

165. Zhong, Z.; Sepramaniam, S.; Chew, X.H.; Wood, K.; Lee, M.A.; Madan, B.; Virshup, D.M. PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers. *Oncogene* 2019, 38, 6662–6677. [CrossRef]

166. Jung, Y.S.; Stratton, S.A.; Lee, S.H.; Kim, M.J.; Jun, S.; Zhang, J.; Zheng, B.; Cervantes, C.L.; Cha, J.H.; Barton, M.C.; et al. TMEM9-v-ATPase activates Wnt/β-catenin signaling via APC lysosomal degradation for liver regeneration and tumorigenesis. *Hepatology* 2020. [CrossRef]

167. Voloshanenko, O.; Erdmann, G.; Danush, T.D.; Augustin, I.; Metzig, M.; Hundsrucker, C.; Kerr, G.; Sandmann, T.; Anchang, B.; et al. Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. *Nat. Commun.* 2013, 4, 2610. [CrossRef]

168. Seino, T.; Kawasaki, S.; Shimokawa, M.; Tamagawa, H.; Toshimitsu, K.; Fujii, M.; Ohta, Y.; Matano, M.; Nanki, K.; Kawasaki, K.; et al. Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. *Cell Stem Cell* 2018, 22, 454–467.e6. [CrossRef]

169. Tammela, T.; Sanchez-Rivera, F.J.; Cetinbas, N.M.; Wu, K.; Joshi, N.S.; Helenius, K.; Park, Y.; Azimi, R.; Kerper, N.R.; Wesselhoeft, R.A.; et al. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. *Nature* 2017, 545, 355–359. [CrossRef]

170. Hou, P.; Ma, X.; Zhang, Q.; Wu, C.J.; Liao, W.; Li, J.; Wang, H.; Zhao, J.; Zhou, X.; Guan, C.; et al. USP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation. *Genes Dev.* 2019, 33, 1361–1366. [CrossRef]

171. Liu, L.; Zhang, Y.; Wong, C.C.; Zhang, J.; Dong, Y.; Li, X.; Kang, W.; Chan, F.K.L.; Sung, J.J.Y.; Yu, J. RNf6 promotes colorectal cancer by activating the Wnt/β-catenin pathway via ubiquitination of TLE3. *Cancer Res.* 2018, 78, 1958–1971. [CrossRef][PubMed]

172. Novellasdemunt, L.; Foglizzo, V.; Cuadrado, L.; Antas, P.; Kucharska, A.; Encheva, V.; Nijhuis, A.P.; Li, V.S.W. USP7 is a tumor-specific WNT activator for APC-mutated colorectal cancer by mediating β-catenin deubiquitination. *Cell Rep.* 2017, 21, 612–627. [CrossRef][PubMed]

173. Gay, D.M.; Riddigwey, R.A.; Muller, M.; Hodder, M.C.; Hedley, A.; Clark, W.; Leach, J.D.; Jackstadt, R.; Nixon, C.; Huels, D.J.; et al. Loss of BCL9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer. *Nat. Commun.* 2019, 10, 723. [CrossRef][PubMed]

174. Deka, J.; Wiedemann, N.; Anderle, P.; Murphy-Seiler, F.; Bultinck, J.; Eyckerman, S.; Stehle, J.C.; Andre, S.; Vilain, N.; Zilian, O.; et al. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. *Cancer Res.* 2010, 70, 6619–6628. [CrossRef]
175. Feng, M.; Jin, J.Q.; Xia, L.; Xiao, T.; Mei, S.; Wang, X.; Huang, X.; Chen, J.; Liu, M.; Chen, C.; et al. Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating T(reg) cells. Sci. Adv. 2019, 5, eaau5240. [CrossRef]

176. Flanagan, D.J.; Barker, N.; Nowell, C.; Clevers, H.; Ernst, M.; Phesse, T.J.; Vincan, E. Loss of the Wnt receptor frizzled 7 in the mouse gastric epithelium is deleterious and triggers rapid repopulation in vivo. Dis. Models Mech. 2017, 10, 971–980. [CrossRef]

177. Flanagan, D.J.; Phesse, T.J.; Barker, N.; Schwab, R.H.; Amin, N.; Malaterre, J.; Stange, D.E.; Nowell, C.J.; Currie, S.A.; Saw, J.T.; et al. Frizzled7 functions as a Wnt receptor in intestinal epithelial Lgr5(+) stem cells. Stem Cell Rep. 2015, 4, 759–767. [CrossRef]

178. Jung, H.Y.; Jun, S.; Lee, M.; Kim, H.C.; Wang, X.; Ji, H.; McCrea, P.D.; Park, J.I. PAF and EZH2 induce Wnt/beta-catenin signaling hyperactivation. Mol. Cell 2013, 52, 193–205. [CrossRef]

179. Kim, M.J.; Xia, B.; Suh, H.N.; Lee, S.H.; Jun, S.; Lien, E.M.; Zhang, J.; Chen, K.; Park, J.I. PAF-Myc-controlled cell stemness is required for intestinal regeneration and tumorigenesis. Dev. Cell 2018, 44, 582–596.e4. [CrossRef] [PubMed]

180. Schutgens, F.; Clevers, H. Human organoids: Tools for understanding biology and treating diseases. Annu. Rev. Pathol. 2020, 15, 211–234. [CrossRef]

181. Sato, T.; Vries, R.G.; Snippert, H.J.; van de Wetering, M.; Barker, N.; Stange, D.E.; van Es, J.H.; Abo, A.; Kujala, P.; Peters, P.J.; et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009, 459, 262–265. [CrossRef] [PubMed]

182. Clevers, H. Modeling development and disease with organoids. Cell 2016, 165, 1586–1597. [CrossRef] [PubMed]

183. Yao, Y.; Xu, X.; Yang, L.; Zhu, J.; Wan, J.; Shen, L.; Xia, F.; Fu, G.; Deng, Y.; Pan, M.; et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell 2020, 26, 17–26.e6. [CrossRef] [PubMed]

184. Vlachogiannis, G.; Hedayat, S.; Vatsiou, A.; Jamin, Y.; Fernández-Mateos, J.; Khan, K.; Lampis, A.; Eason, K.; Huntingford, I.; Burke, R.; et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 2018, 359, 920–926. [CrossRef]

185. Nagle, P.W.; Plukker, J.T.M.; Muijs, C.T.; van Luijk, P.; Coppes, R.P. Patient-derived tumor organoids for prediction of cancer treatment response. Semin. Cancer Biol. 2018, 53, 258–264. [CrossRef]

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.